JP5639197B2 - 医薬組成物のためのヘテロシクロアルキル含有チエノピリミジン - Google Patents
医薬組成物のためのヘテロシクロアルキル含有チエノピリミジン Download PDFInfo
- Publication number
- JP5639197B2 JP5639197B2 JP2012554347A JP2012554347A JP5639197B2 JP 5639197 B2 JP5639197 B2 JP 5639197B2 JP 2012554347 A JP2012554347 A JP 2012554347A JP 2012554347 A JP2012554347 A JP 2012554347A JP 5639197 B2 JP5639197 B2 JP 5639197B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- pyrimidine
- thieno
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 24
- 125000000592 heterocycloalkyl group Chemical group 0.000 title 1
- -1 R 4 is Chemical group 0.000 claims description 119
- 150000001875 compounds Chemical class 0.000 claims description 118
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 55
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 35
- 201000010099 disease Diseases 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- 230000002265 prevention Effects 0.000 claims description 29
- 206010012601 diabetes mellitus Diseases 0.000 claims description 27
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 16
- 125000003386 piperidinyl group Chemical group 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 208000027866 inflammatory disease Diseases 0.000 claims description 13
- 208000030159 metabolic disease Diseases 0.000 claims description 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000002883 imidazolyl group Chemical group 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 7
- 125000002393 azetidinyl group Chemical group 0.000 claims description 6
- 125000004069 aziridinyl group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 230000023852 carbohydrate metabolic process Effects 0.000 claims description 5
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 5
- 230000037356 lipid metabolism Effects 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 239000003472 antidiabetic agent Substances 0.000 claims description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 claims description 2
- 239000000883 anti-obesity agent Substances 0.000 claims description 2
- 229940125708 antidiabetic agent Drugs 0.000 claims description 2
- 239000003524 antilipemic agent Substances 0.000 claims description 2
- 229940125710 antiobesity agent Drugs 0.000 claims description 2
- 229940127218 antiplatelet drug Drugs 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 2
- 230000006978 adaptation Effects 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 165
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 108
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 76
- 239000000203 mixture Substances 0.000 description 68
- 238000004128 high performance liquid chromatography Methods 0.000 description 63
- 238000006243 chemical reaction Methods 0.000 description 61
- 238000000034 method Methods 0.000 description 60
- 230000014759 maintenance of location Effects 0.000 description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 53
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 49
- 239000000243 solution Substances 0.000 description 49
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 37
- 239000000543 intermediate Substances 0.000 description 36
- FLDSMVTWEZKONL-AWEZNQCLSA-N 5,5-dimethyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,4,7,8-tetrahydrooxepino[4,5-c]pyrazole-3-carboxamide Chemical compound CC1(CC2=C(NN=C2C(=O)N[C@@H]2C(N(C3=C(OC2)C=CC=C3)C)=O)CCO1)C FLDSMVTWEZKONL-AWEZNQCLSA-N 0.000 description 34
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 34
- 239000002904 solvent Substances 0.000 description 34
- 239000003643 water by type Substances 0.000 description 33
- 108091000080 Phosphotransferase Proteins 0.000 description 32
- 102000020233 phosphotransferase Human genes 0.000 description 32
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 239000002253 acid Substances 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- 101710139011 MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 28
- 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 238000004587 chromatography analysis Methods 0.000 description 27
- 239000000047 product Substances 0.000 description 27
- 239000005973 Carvone Substances 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 25
- 239000000725 suspension Substances 0.000 description 25
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 19
- 208000035475 disorder Diseases 0.000 description 19
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- 239000012071 phase Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- 101710138999 MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 description 16
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 16
- CUNUJTDTFOTOJA-UHFFFAOYSA-N methyl 4-chloro-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C1=NC(Cl)=C2C(C)=C(C(=O)OC)SC2=N1 CUNUJTDTFOTOJA-UHFFFAOYSA-N 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 15
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 15
- 229910021529 ammonia Inorganic materials 0.000 description 15
- 230000002757 inflammatory effect Effects 0.000 description 14
- 150000004702 methyl esters Chemical class 0.000 description 14
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- 229940002612 prodrug Drugs 0.000 description 13
- 239000000651 prodrug Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 102100027304 Eukaryotic translation initiation factor 4E Human genes 0.000 description 12
- 101710091918 Eukaryotic translation initiation factor 4E Proteins 0.000 description 12
- 230000005526 G1 to G0 transition Effects 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000002209 hydrophobic effect Effects 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 11
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 201000004681 Psoriasis Diseases 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- UGJKNLAPCQLIMS-GFCCVEGCSA-N 4-[4-fluoro-2-[(3r)-piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCCNC1 UGJKNLAPCQLIMS-GFCCVEGCSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 206010003246 arthritis Diseases 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 235000020824 obesity Nutrition 0.000 description 9
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical class C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 206010040070 Septic Shock Diseases 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 8
- 235000019253 formic acid Nutrition 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 206010007559 Cardiac failure congestive Diseases 0.000 description 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 7
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 108020005176 AU Rich Elements Proteins 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 206010009900 Colitis ulcerative Diseases 0.000 description 6
- 208000011231 Crohn disease Diseases 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 6
- 208000025747 Rheumatic disease Diseases 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 description 6
- 208000038016 acute inflammation Diseases 0.000 description 6
- 230000006022 acute inflammation Effects 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 208000037976 chronic inflammation Diseases 0.000 description 6
- 230000006020 chronic inflammation Effects 0.000 description 6
- 230000016396 cytokine production Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000002875 fluorescence polarization Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000000021 kinase assay Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 230000000552 rheumatic effect Effects 0.000 description 6
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 6
- 230000036303 septic shock Effects 0.000 description 6
- UIJXHKXIOCDSEB-QMMMGPOBSA-N tert-butyl (3s)-3-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H](O)C1 UIJXHKXIOCDSEB-QMMMGPOBSA-N 0.000 description 6
- AVZWTWRGLRYTSY-LLVKDONJSA-N 4-[4-fluoro-2-[(3r)-oxolan-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCOC1 AVZWTWRGLRYTSY-LLVKDONJSA-N 0.000 description 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 5
- 206010018364 Glomerulonephritis Diseases 0.000 description 5
- 201000009906 Meningitis Diseases 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 208000006374 Uterine Cervicitis Diseases 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 206010008323 cervicitis Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- GXZQHMHLHHUHAM-UHFFFAOYSA-N methyl pyrimidine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=N1 GXZQHMHLHHUHAM-UHFFFAOYSA-N 0.000 description 5
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 5
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 5
- 235000015320 potassium carbonate Nutrition 0.000 description 5
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 201000004595 synovitis Diseases 0.000 description 5
- AGPQUUHYPJGNMY-LBPRGKRZSA-N tert-butyl (3s)-3-(2-amino-5-fluorophenoxy)piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC[C@@H]1OC1=CC(F)=CC=C1N AGPQUUHYPJGNMY-LBPRGKRZSA-N 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- QDKIYDGHCFZBGC-UHFFFAOYSA-N 2-fluoro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1F QDKIYDGHCFZBGC-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- SUDVEGFIKXLXAX-UHFFFAOYSA-N 4-[4-fluoro-2-(1-methylsulfonylpyrrolidin-3-yl)oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1OC1CCN(S(C)(=O)=O)C1 SUDVEGFIKXLXAX-UHFFFAOYSA-N 0.000 description 4
- OCFSBXLPNKYLLB-UHFFFAOYSA-N 4-[4-fluoro-2-(oxan-4-yloxy)anilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1OC1CCOCC1 OCFSBXLPNKYLLB-UHFFFAOYSA-N 0.000 description 4
- LNNZEIFYTIOHNS-OAHLLOKOSA-N 4-[4-fluoro-2-[(3r)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCCN(C(=O)OC(C)(C)C)C1 LNNZEIFYTIOHNS-OAHLLOKOSA-N 0.000 description 4
- BEYCMPVDBWSHDX-AWEZNQCLSA-N 4-[4-fluoro-2-[(3s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCN(C(=O)OC(C)(C)C)C1 BEYCMPVDBWSHDX-AWEZNQCLSA-N 0.000 description 4
- UGJKNLAPCQLIMS-LBPRGKRZSA-N 4-[4-fluoro-2-[(3s)-piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCNC1 UGJKNLAPCQLIMS-LBPRGKRZSA-N 0.000 description 4
- WMCBIHXIVHMSIL-UHFFFAOYSA-N 5-methyl-4-[[2-(oxan-4-yloxy)pyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=CN=C1OC1CCOCC1 WMCBIHXIVHMSIL-UHFFFAOYSA-N 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 0 CC(C*)c1n[o]cn1 Chemical compound CC(C*)c1n[o]cn1 0.000 description 4
- 206010006895 Cachexia Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 4
- 208000004145 Endometritis Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 4
- 208000019693 Lung disease Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 4
- 239000012317 TBTU Substances 0.000 description 4
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 201000001883 cholelithiasis Diseases 0.000 description 4
- 229960000684 cytarabine Drugs 0.000 description 4
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 206010014665 endocarditis Diseases 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- WGGOASLTIQFCAE-CYBMUJFWSA-N methyl 4-[4-fluoro-2-[(3r)-piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCCNC1 WGGOASLTIQFCAE-CYBMUJFWSA-N 0.000 description 4
- GLBQHCWGCWWYRC-INIZCTEOSA-N methyl 4-[4-fluoro-2-[(3s)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCN(C(=O)OC(C)(C)C)C1 GLBQHCWGCWWYRC-INIZCTEOSA-N 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- KCXPMWBUHBHFQI-LBPRGKRZSA-N tert-butyl (3s)-3-[2-amino-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC[C@@H]1OC1=CC(C(F)(F)F)=CC=C1N KCXPMWBUHBHFQI-LBPRGKRZSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010043778 thyroiditis Diseases 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- BHDLTOUYJMTTTM-RXMQYKEDSA-N (3r)-oxan-3-ol Chemical compound O[C@@H]1CCCOC1 BHDLTOUYJMTTTM-RXMQYKEDSA-N 0.000 description 3
- XDPCNPCKDGQBAN-BYPYZUCNSA-N (3s)-oxolan-3-ol Chemical compound O[C@H]1CCOC1 XDPCNPCKDGQBAN-BYPYZUCNSA-N 0.000 description 3
- KNMBWRWHUFZCAP-UHFFFAOYSA-N 2-(oxan-4-yloxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1CCOCC1 KNMBWRWHUFZCAP-UHFFFAOYSA-N 0.000 description 3
- AMMHPHJOESJBAR-MRVPVSSYSA-N 2-[(3r)-oxan-3-yl]oxypyridin-3-amine Chemical compound NC1=CC=CN=C1O[C@H]1COCCC1 AMMHPHJOESJBAR-MRVPVSSYSA-N 0.000 description 3
- WLNBHKZFBPTGQJ-SSDOTTSWSA-N 2-[(3r)-oxolan-3-yl]oxypyridin-3-amine Chemical compound NC1=CC=CN=C1O[C@H]1COCC1 WLNBHKZFBPTGQJ-SSDOTTSWSA-N 0.000 description 3
- QYPJCUSQGQBSNQ-SSDOTTSWSA-N 3-nitro-2-[(3r)-oxolan-3-yl]oxypyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1O[C@H]1COCC1 QYPJCUSQGQBSNQ-SSDOTTSWSA-N 0.000 description 3
- QYPJCUSQGQBSNQ-ZETCQYMHSA-N 3-nitro-2-[(3s)-oxolan-3-yl]oxypyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1O[C@@H]1COCC1 QYPJCUSQGQBSNQ-ZETCQYMHSA-N 0.000 description 3
- AEJFNMXSZKHUHP-ZDUSSCGKSA-N 4-[4-cyano-2-[(3s)-piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(C#N)C=C1O[C@H]1CCCNC1 AEJFNMXSZKHUHP-ZDUSSCGKSA-N 0.000 description 3
- QMPFIGSMGLFJNR-UHFFFAOYSA-N 4-fluoro-2-(oxan-4-yloxy)aniline Chemical compound NC1=CC=C(F)C=C1OC1CCOCC1 QMPFIGSMGLFJNR-UHFFFAOYSA-N 0.000 description 3
- RTWPTPGSOQNMOI-SECBINFHSA-N 4-fluoro-2-[(3r)-oxan-3-yl]oxyaniline Chemical compound NC1=CC=C(F)C=C1O[C@H]1COCCC1 RTWPTPGSOQNMOI-SECBINFHSA-N 0.000 description 3
- CIGZVQFJNZCJHF-MRVPVSSYSA-N 4-fluoro-2-[(3r)-oxolan-3-yl]oxyaniline Chemical compound NC1=CC=C(F)C=C1O[C@H]1COCC1 CIGZVQFJNZCJHF-MRVPVSSYSA-N 0.000 description 3
- RTWPTPGSOQNMOI-VIFPVBQESA-N 4-fluoro-2-[(3s)-oxan-3-yl]oxyaniline Chemical compound NC1=CC=C(F)C=C1O[C@@H]1COCCC1 RTWPTPGSOQNMOI-VIFPVBQESA-N 0.000 description 3
- CIGZVQFJNZCJHF-QMMMGPOBSA-N 4-fluoro-2-[(3s)-oxolan-3-yl]oxyaniline Chemical compound NC1=CC=C(F)C=C1O[C@@H]1COCC1 CIGZVQFJNZCJHF-QMMMGPOBSA-N 0.000 description 3
- QQURWFRNETXFTN-UHFFFAOYSA-N 5-fluoro-2-nitrophenol Chemical compound OC1=CC(F)=CC=C1[N+]([O-])=O QQURWFRNETXFTN-UHFFFAOYSA-N 0.000 description 3
- ATFWQHCPGHGXND-LBPRGKRZSA-N 5-methyl-4-[2-[(3s)-piperidin-3-yl]oxy-4-(trifluoromethyl)anilino]thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(C(F)(F)F)C=C1O[C@H]1CCCNC1 ATFWQHCPGHGXND-LBPRGKRZSA-N 0.000 description 3
- GUHWVBWAJUDPGE-SNVBAGLBSA-N 5-methyl-4-[[2-[(3r)-oxolan-3-yl]oxypyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=CN=C1O[C@@H]1CCOC1 GUHWVBWAJUDPGE-SNVBAGLBSA-N 0.000 description 3
- KCCICOFPLAGOHN-SNVBAGLBSA-N 5-methyl-4-[[2-[(3r)-oxolan-3-yl]oxypyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=CN=C1O[C@@H]1CCOC1 KCCICOFPLAGOHN-SNVBAGLBSA-N 0.000 description 3
- KCCICOFPLAGOHN-JTQLQIEISA-N 5-methyl-4-[[2-[(3s)-oxolan-3-yl]oxypyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=CN=C1O[C@H]1CCOC1 KCCICOFPLAGOHN-JTQLQIEISA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- JEGMWWXJUXDNJN-UHFFFAOYSA-N CC1CNCCC1 Chemical compound CC1CNCCC1 JEGMWWXJUXDNJN-UHFFFAOYSA-N 0.000 description 3
- 108010055166 Chemokine CCL5 Proteins 0.000 description 3
- 206010010741 Conjunctivitis Diseases 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010008165 Etanercept Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 201000002481 Myositis Diseases 0.000 description 3
- UQPMANVRZYYQMD-UHFFFAOYSA-N N3-(4-fluorophenyl)-2H-pyrazolo[3,4-d]pyrimidine-3,4-diamine Chemical compound C=12C(N)=NC=NC2=NNC=1NC1=CC=C(F)C=C1 UQPMANVRZYYQMD-UHFFFAOYSA-N 0.000 description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000011097 chromatography purification Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000007565 gingivitis Diseases 0.000 description 3
- 229960005150 glycerol Drugs 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- OVWSWGNMOPUTFS-UHFFFAOYSA-N methyl 4-(4-fluoro-2-hydroxyanilino)-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O OVWSWGNMOPUTFS-UHFFFAOYSA-N 0.000 description 3
- LZCONRMFWONWLA-OAHLLOKOSA-N methyl 4-[4-fluoro-2-[(3r)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCN(C(=O)OC(C)(C)C)C1 LZCONRMFWONWLA-OAHLLOKOSA-N 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- SZANJLCRTRGKNY-RDJZCZTQSA-N n-[(1s,2s)-2-hydroxycyclopentyl]-5-methyl-4-[[2-(oxan-4-yloxy)pyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(=O)N[C@@H]3[C@H](CCC3)O)SC2=NC=NC=1NC1=CC=CN=C1OC1CCOCC1 SZANJLCRTRGKNY-RDJZCZTQSA-N 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 206010035653 pneumoconiosis Diseases 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229960000953 salsalate Drugs 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- AGPQUUHYPJGNMY-GFCCVEGCSA-N tert-butyl (3r)-3-(2-amino-5-fluorophenoxy)piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC[C@H]1OC1=CC(F)=CC=C1N AGPQUUHYPJGNMY-GFCCVEGCSA-N 0.000 description 3
- LVXLLFDMFHAYBU-NSHDSACASA-N tert-butyl (3s)-3-(3-aminopyridin-2-yl)oxypiperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC[C@@H]1OC1=NC=CC=C1N LVXLLFDMFHAYBU-NSHDSACASA-N 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NLQGSAFCBLOMEO-KRWDZBQOSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-fluoro-2-[(3s)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)ON3C(CCC3=O)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCN(C(=O)OC(C)(C)C)C1 NLQGSAFCBLOMEO-KRWDZBQOSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- ILQAQYFIVVDQEO-SECBINFHSA-N (3r)-3-(5-fluoro-2-nitrophenoxy)oxane Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1O[C@H]1COCCC1 ILQAQYFIVVDQEO-SECBINFHSA-N 0.000 description 2
- ODRGFLVESQITSU-MRVPVSSYSA-N (3r)-3-(5-fluoro-2-nitrophenoxy)oxolane Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1O[C@H]1COCC1 ODRGFLVESQITSU-MRVPVSSYSA-N 0.000 description 2
- ILQAQYFIVVDQEO-VIFPVBQESA-N (3s)-3-(5-fluoro-2-nitrophenoxy)oxane Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1O[C@@H]1COCCC1 ILQAQYFIVVDQEO-VIFPVBQESA-N 0.000 description 2
- ODRGFLVESQITSU-QMMMGPOBSA-N (3s)-3-(5-fluoro-2-nitrophenoxy)oxolane Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1O[C@@H]1COCC1 ODRGFLVESQITSU-QMMMGPOBSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 2
- SUVMJINMZCTBEL-AAEUAGOBSA-N 1-o-tert-butyl 2-o-methyl (2s,4s)-4-(2-amino-5-fluorophenoxy)pyrrolidine-1,2-dicarboxylate Chemical compound C1N(C(=O)OC(C)(C)C)[C@H](C(=O)OC)C[C@@H]1OC1=CC(F)=CC=C1N SUVMJINMZCTBEL-AAEUAGOBSA-N 0.000 description 2
- KCHWVWYSYIAREP-AAEUAGOBSA-N 1-o-tert-butyl 2-o-methyl (2s,4s)-4-(5-fluoro-2-nitrophenoxy)pyrrolidine-1,2-dicarboxylate Chemical compound C1N(C(=O)OC(C)(C)C)[C@H](C(=O)OC)C[C@@H]1OC1=CC(F)=CC=C1[N+]([O-])=O KCHWVWYSYIAREP-AAEUAGOBSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- GLGVPKRGJAQOBH-JTQLQIEISA-N 2,2,2-trifluoro-1-[(3s)-3-(5-methyl-2-nitrophenoxy)piperidin-1-yl]ethanone Chemical compound CC1=CC=C([N+]([O-])=O)C(O[C@@H]2CN(CCC2)C(=O)C(F)(F)F)=C1 GLGVPKRGJAQOBH-JTQLQIEISA-N 0.000 description 2
- RJXOVESYJFXCGI-UHFFFAOYSA-N 2,4-difluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1F RJXOVESYJFXCGI-UHFFFAOYSA-N 0.000 description 2
- WLNBHKZFBPTGQJ-ZETCQYMHSA-N 2-[(3s)-oxolan-3-yl]oxypyridin-3-amine Chemical compound NC1=CC=CN=C1O[C@@H]1COCC1 WLNBHKZFBPTGQJ-ZETCQYMHSA-N 0.000 description 2
- JVYROUWXXSWCMI-UHFFFAOYSA-N 2-bromo-1,1-difluoroethane Chemical compound FC(F)CBr JVYROUWXXSWCMI-UHFFFAOYSA-N 0.000 description 2
- PNWGYIAXNDWHPF-MRVPVSSYSA-N 3-nitro-2-[(3r)-oxan-3-yl]oxypyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1O[C@H]1COCCC1 PNWGYIAXNDWHPF-MRVPVSSYSA-N 0.000 description 2
- UBOPIEBCGHAULF-UHFFFAOYSA-N 4-(5-fluoro-2-nitrophenoxy)oxane Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1OC1CCOCC1 UBOPIEBCGHAULF-UHFFFAOYSA-N 0.000 description 2
- PITBTDVPMLZOGY-CQSZACIVSA-N 4-[2-[(3r)-1-acetylpiperidin-3-yl]oxy-4-fluoroanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C1N(C(=O)C)CCC[C@H]1OC1=CC(F)=CC=C1NC1=NC=NC2=C1C(C)=C(C(N)=O)S2 PITBTDVPMLZOGY-CQSZACIVSA-N 0.000 description 2
- HBVXAOKNEBODSR-CYBMUJFWSA-N 4-[2-[(3r)-1-acetylpyrrolidin-3-yl]oxy-4-fluoroanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C1N(C(=O)C)CC[C@H]1OC1=CC(F)=CC=C1NC1=NC=NC2=C1C(C)=C(C(N)=O)S2 HBVXAOKNEBODSR-CYBMUJFWSA-N 0.000 description 2
- POTCNDAYHDXXFA-UHFFFAOYSA-N 4-[2-[1-[2-(dimethylamino)acetyl]pyrrolidin-3-yl]oxy-4-fluoroanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C1N(C(=O)CN(C)C)CCC1OC1=CC(F)=CC=C1NC1=NC=NC2=C1C(C)=C(C(N)=O)S2 POTCNDAYHDXXFA-UHFFFAOYSA-N 0.000 description 2
- VOJUPSCWJUTGER-UHFFFAOYSA-N 4-[2-[1-[2-(dimethylamino)acetyl]pyrrolidin-3-yl]oxy-4-fluoroanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C1N(C(=O)CN(C)C)CCC1OC1=CC(F)=CC=C1NC1=NC=NC2=C1C(C)=C(C(O)=O)S2 VOJUPSCWJUTGER-UHFFFAOYSA-N 0.000 description 2
- BYLKZSYAAXKABV-LBPRGKRZSA-N 4-[4-chloro-2-[(3s)-piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(Cl)C=C1O[C@H]1CCCNC1 BYLKZSYAAXKABV-LBPRGKRZSA-N 0.000 description 2
- IUTGZVTYASHFJX-UHFFFAOYSA-N 4-[4-fluoro-2-(1-methylsulfonylpyrrolidin-3-yl)oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1OC1CCN(S(C)(=O)=O)C1 IUTGZVTYASHFJX-UHFFFAOYSA-N 0.000 description 2
- LMAGNXZYFXHOKD-GFCCVEGCSA-N 4-[4-fluoro-2-[(3r)-oxan-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCCOC1 LMAGNXZYFXHOKD-GFCCVEGCSA-N 0.000 description 2
- CDYBZFLTXIMYDW-RFVHGSKJSA-N 4-[4-fluoro-2-[(3r)-pyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide;hydrochloride Chemical compound Cl.C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCNC1 CDYBZFLTXIMYDW-RFVHGSKJSA-N 0.000 description 2
- NYCAPTLVSZRVON-HNNXBMFYSA-N 4-[4-fluoro-2-[(3s)-1-(2-methoxyethyl)piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C1N(CCOC)CCC[C@@H]1OC1=CC(F)=CC=C1NC1=NC=NC2=C1C(C)=C(C(N)=O)S2 NYCAPTLVSZRVON-HNNXBMFYSA-N 0.000 description 2
- GOLYWZDVGKYQBR-ZDUSSCGKSA-N 4-[4-fluoro-2-[(3s)-1-methylsulfonylpiperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCN(S(C)(=O)=O)C1 GOLYWZDVGKYQBR-ZDUSSCGKSA-N 0.000 description 2
- AVZWTWRGLRYTSY-NSHDSACASA-N 4-[4-fluoro-2-[(3s)-oxolan-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCOC1 AVZWTWRGLRYTSY-NSHDSACASA-N 0.000 description 2
- NCASZHLAKYQXRI-HNNXBMFYSA-N 4-[4-fluoro-2-[(3s)-piperidin-3-yl]oxyanilino]-5-methyl-n-(1-methylpyrazol-3-yl)thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(=O)NC3=NN(C)C=C3)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCNC1 NCASZHLAKYQXRI-HNNXBMFYSA-N 0.000 description 2
- OWWVFEGXRCWFKL-LBPRGKRZSA-N 4-[4-fluoro-2-[(3s)-piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCNC1 OWWVFEGXRCWFKL-LBPRGKRZSA-N 0.000 description 2
- CDYBZFLTXIMYDW-MERQFXBCSA-N 4-[4-fluoro-2-[(3s)-pyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide;hydrochloride Chemical compound Cl.C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCNC1 CDYBZFLTXIMYDW-MERQFXBCSA-N 0.000 description 2
- PCBTXOCMGDTVCP-UHFFFAOYSA-N 4-[4-fluoro-2-[1-(2-methoxyacetyl)pyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C1N(C(=O)COC)CCC1OC1=CC(F)=CC=C1NC1=NC=NC2=C1C(C)=C(C(N)=O)S2 PCBTXOCMGDTVCP-UHFFFAOYSA-N 0.000 description 2
- TZMQNENJNIDXNI-JTQLQIEISA-N 4-amino-3-[(3s)-1-(2,2,2-trifluoroacetyl)piperidin-3-yl]oxybenzonitrile Chemical compound NC1=CC=C(C#N)C=C1O[C@@H]1CN(C(=O)C(F)(F)F)CCC1 TZMQNENJNIDXNI-JTQLQIEISA-N 0.000 description 2
- PTJOXWMWUYAUDP-HNNXBMFYSA-N 5-methyl-4-[2-[(3s)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]oxy-4-(trifluoromethyl)anilino]thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=C(C(F)(F)F)C=C1O[C@H]1CCCN(C(=O)OC(C)(C)C)C1 PTJOXWMWUYAUDP-HNNXBMFYSA-N 0.000 description 2
- IISDGMDLZAMACD-ZDUSSCGKSA-N 5-methyl-4-[4-methyl-2-[(3s)-piperidin-3-yl]oxyanilino]thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(C)C=C1O[C@H]1CCCNC1 IISDGMDLZAMACD-ZDUSSCGKSA-N 0.000 description 2
- ZEHIRVLEDIGHQL-LLVKDONJSA-N 5-methyl-4-[[2-[(3r)-oxan-3-yl]oxypyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=CN=C1O[C@@H]1CCCOC1 ZEHIRVLEDIGHQL-LLVKDONJSA-N 0.000 description 2
- HIIKFCMWXPBGCZ-AWEZNQCLSA-N 5-methyl-4-[[2-[(3s)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]oxypyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=CN=C1O[C@H]1CCCN(C(=O)OC(C)(C)C)C1 HIIKFCMWXPBGCZ-AWEZNQCLSA-N 0.000 description 2
- ULKFYEYMXNWUMZ-NSHDSACASA-N 5-methyl-4-[[2-[(3s)-piperidin-3-yl]oxypyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=CN=C1O[C@H]1CCCNC1 ULKFYEYMXNWUMZ-NSHDSACASA-N 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 206010006811 Bursitis Diseases 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 108010013198 Daptomycin Proteins 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 101000573522 Homo sapiens MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 2
- 101001018978 Homo sapiens MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 description 2
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 2
- 241000701027 Human herpesvirus 6 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 206010072877 Intestinal fibrosis Diseases 0.000 description 2
- 206010022941 Iridocyclitis Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 208000011200 Kawasaki disease Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 201000008197 Laryngitis Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 208000011682 Mitral valve disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000003926 Myelitis Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 2
- 206010064550 Myocarditis post infection Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
- 206010037575 Pustular psoriasis Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 201000002661 Spondylitis Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 2
- 208000000491 Tendinopathy Diseases 0.000 description 2
- 206010043255 Tendonitis Diseases 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 206010043780 Thyroiditis acute Diseases 0.000 description 2
- 206010043784 Thyroiditis subacute Diseases 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 2
- 201000006498 acute thyroiditis Diseases 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 201000004612 anterior uveitis Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000006583 body weight regulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000009267 bronchiectasis Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000001352 cholecystitis Diseases 0.000 description 2
- 208000002849 chondrocalcinosis Diseases 0.000 description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000010549 co-Evaporation Methods 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 2
- 229960005484 daptomycin Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 208000007784 diverticulitis Diseases 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 208000019258 ear infection Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 208000001606 epiglottitis Diseases 0.000 description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 2
- 229960004563 eprosartan Drugs 0.000 description 2
- 208000006881 esophagitis Diseases 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
- 229960000201 isosorbide dinitrate Drugs 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000003265 lymphadenitis Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- AAYDPGUAZXNVQR-UHFFFAOYSA-N methyl 4-(4-fluoro-2-pyrrolidin-3-yloxyanilino)-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1OC1CCNC1 AAYDPGUAZXNVQR-UHFFFAOYSA-N 0.000 description 2
- NFSVWPGVWBYEPJ-STQMWFEESA-N methyl 4-[2-[[(6s,7as)-3-oxo-5,6,7,7a-tetrahydro-1h-pyrrolo[1,2-c][1,3]oxazol-6-yl]oxy]-4-fluoroanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CN2C(=O)OC[C@@H]2C1 NFSVWPGVWBYEPJ-STQMWFEESA-N 0.000 description 2
- RODQFIOCXAPWEP-ZDUSSCGKSA-N methyl 4-[4-chloro-2-[(3s)-1-(2,2,2-trifluoroacetyl)piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(Cl)C=C1O[C@H]1CCCN(C(=O)C(F)(F)F)C1 RODQFIOCXAPWEP-ZDUSSCGKSA-N 0.000 description 2
- QYNHCHNNFMWPKS-UHFFFAOYSA-N methyl 4-[4-fluoro-2-(1-methylsulfonylpyrrolidin-3-yl)oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1OC1CCN(S(C)(=O)=O)C1 QYNHCHNNFMWPKS-UHFFFAOYSA-N 0.000 description 2
- AAYDPGUAZXNVQR-GFCCVEGCSA-N methyl 4-[4-fluoro-2-[(3r)-pyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCNC1 AAYDPGUAZXNVQR-GFCCVEGCSA-N 0.000 description 2
- WGGOASLTIQFCAE-ZDUSSCGKSA-N methyl 4-[4-fluoro-2-[(3s)-piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCNC1 WGGOASLTIQFCAE-ZDUSSCGKSA-N 0.000 description 2
- LZCONRMFWONWLA-UHFFFAOYSA-N methyl 4-[4-fluoro-2-[1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1OC1CCN(C(=O)OC(C)(C)C)C1 LZCONRMFWONWLA-UHFFFAOYSA-N 0.000 description 2
- YQNCEIRQPPXNPU-INIZCTEOSA-N methyl 5-methyl-4-[2-[(3s)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]oxy-4-(trifluoromethyl)anilino]thieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(C(F)(F)F)C=C1O[C@H]1CCCN(C(=O)OC(C)(C)C)C1 YQNCEIRQPPXNPU-INIZCTEOSA-N 0.000 description 2
- YPCCGICGDUVHDV-UHFFFAOYSA-N methyl 5-methyl-4-[[2-(oxan-4-yloxy)pyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=CN=C1OC1CCOCC1 YPCCGICGDUVHDV-UHFFFAOYSA-N 0.000 description 2
- NGYGDBDFOHWKBJ-LLVKDONJSA-N methyl 5-methyl-4-[[2-[(3r)-oxolan-3-yl]oxypyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=CN=C1O[C@@H]1CCOC1 NGYGDBDFOHWKBJ-LLVKDONJSA-N 0.000 description 2
- NGYGDBDFOHWKBJ-NSHDSACASA-N methyl 5-methyl-4-[[2-[(3s)-oxolan-3-yl]oxypyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=CN=C1O[C@H]1CCOC1 NGYGDBDFOHWKBJ-NSHDSACASA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- YWUNKWRWAHSHGU-CYBMUJFWSA-N n-(2-hydroxyethyl)-5-methyl-4-[[2-[(3r)-oxan-3-yl]oxypyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(=O)NCCO)SC2=NC=NC=1NC1=CC=CN=C1O[C@@H]1CCCOC1 YWUNKWRWAHSHGU-CYBMUJFWSA-N 0.000 description 2
- FHTGZDVYPCEHFQ-UHFFFAOYSA-N n-methylpiperidin-4-amine Chemical compound CNC1CCNCC1 FHTGZDVYPCEHFQ-UHFFFAOYSA-N 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 208000001297 phlebitis Diseases 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 201000007529 rheumatic myocarditis Diseases 0.000 description 2
- 208000021870 rheumatic pericarditis Diseases 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 201000005671 spondyloarthropathy Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 201000007497 subacute thyroiditis Diseases 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 201000004415 tendinitis Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- RFGZZDXONLMPOL-RYUDHWBXSA-N tert-butyl (2s,4s)-4-(2-amino-5-fluorophenoxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound C1[C@@H](CO)N(C(=O)OC(C)(C)C)C[C@H]1OC1=CC(F)=CC=C1N RFGZZDXONLMPOL-RYUDHWBXSA-N 0.000 description 2
- ORHGKGTXFKEMPE-GFCCVEGCSA-N tert-butyl (3r)-3-(5-fluoro-2-nitrophenoxy)piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC[C@H]1OC1=CC(F)=CC=C1[N+]([O-])=O ORHGKGTXFKEMPE-GFCCVEGCSA-N 0.000 description 2
- KWQRKOSMSFLBTJ-MRVPVSSYSA-N tert-butyl (3r)-3-methylsulfonyloxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](OS(C)(=O)=O)C1 KWQRKOSMSFLBTJ-MRVPVSSYSA-N 0.000 description 2
- ORHGKGTXFKEMPE-LBPRGKRZSA-N tert-butyl (3s)-3-(5-fluoro-2-nitrophenoxy)piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC[C@@H]1OC1=CC(F)=CC=C1[N+]([O-])=O ORHGKGTXFKEMPE-LBPRGKRZSA-N 0.000 description 2
- JESYWQCHFPXCQW-HNNXBMFYSA-N tert-butyl (3s)-3-[2-[(6-carbamoyl-5-methylthieno[2,3-d]pyrimidin-4-yl)amino]-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(C(F)(F)F)C=C1O[C@H]1CCCN(C(=O)OC(C)(C)C)C1 JESYWQCHFPXCQW-HNNXBMFYSA-N 0.000 description 2
- OAZICBINFQYIHY-AWEZNQCLSA-N tert-butyl (3s)-3-[2-[(6-carbamoyl-5-methylthieno[2,3-d]pyrimidin-4-yl)amino]-5-fluorophenoxy]pyrrolidine-1-carboxylate Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCN(C(=O)OC(C)(C)C)C1 OAZICBINFQYIHY-AWEZNQCLSA-N 0.000 description 2
- DLGFJEKRTCKKKI-SFHVURJKSA-N tert-butyl (3s)-3-[5-fluoro-2-[[5-methyl-6-[(1-methylpyrazol-3-yl)carbamoyl]thieno[2,3-d]pyrimidin-4-yl]amino]phenoxy]piperidine-1-carboxylate Chemical compound C=12C(C)=C(C(=O)NC3=NN(C)C=C3)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCN(C(=O)OC(C)(C)C)C1 DLGFJEKRTCKKKI-SFHVURJKSA-N 0.000 description 2
- APCBTRDHCDOPNY-ZETCQYMHSA-N tert-butyl (3s)-3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](O)C1 APCBTRDHCDOPNY-ZETCQYMHSA-N 0.000 description 2
- KWQRKOSMSFLBTJ-UHFFFAOYSA-N tert-butyl 3-methylsulfonyloxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(C)(=O)=O)C1 KWQRKOSMSFLBTJ-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000005060 thrombophlebitis Diseases 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 208000000143 urethritis Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 208000002003 vulvitis Diseases 0.000 description 2
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- SPAIHGRDBDFVEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) pyrimidine-4-carboxylate Chemical compound O=C1N(C(CC1)=O)OC(=O)C1=CC=NC=N1 SPAIHGRDBDFVEJ-UHFFFAOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- XDPCNPCKDGQBAN-SCSAIBSYSA-N (3r)-oxolan-3-ol Chemical compound O[C@@H]1CCOC1 XDPCNPCKDGQBAN-SCSAIBSYSA-N 0.000 description 1
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 1
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
- SRKGZXIJDGWVAI-GVAVTCRGSA-M (e,3r)-7-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)C1=NC(C(C)(C)C)=CC(C=2C=CC(F)=CC=2)=C1\C=C\C(O)C[C@@H](O)CC([O-])=O SRKGZXIJDGWVAI-GVAVTCRGSA-M 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- CAOWCUFYVLBJGQ-VIFPVBQESA-N 1-[(3s)-3-(2-amino-5-chlorophenoxy)piperidin-1-yl]-2,2,2-trifluoroethanone Chemical compound NC1=CC=C(Cl)C=C1O[C@@H]1CN(C(=O)C(F)(F)F)CCC1 CAOWCUFYVLBJGQ-VIFPVBQESA-N 0.000 description 1
- NBOCPJJJXLHACC-JTQLQIEISA-N 1-[(3s)-3-(2-amino-5-methylphenoxy)piperidin-1-yl]-2,2,2-trifluoroethanone Chemical compound CC1=CC=C(N)C(O[C@@H]2CN(CCC2)C(=O)C(F)(F)F)=C1 NBOCPJJJXLHACC-JTQLQIEISA-N 0.000 description 1
- OEBPSWXKGQFJOP-VIFPVBQESA-N 1-[(3s)-3-(5-chloro-2-nitrophenoxy)piperidin-1-yl]-2,2,2-trifluoroethanone Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1O[C@@H]1CN(C(=O)C(F)(F)F)CCC1 OEBPSWXKGQFJOP-VIFPVBQESA-N 0.000 description 1
- MTHQFRHZRCYLOP-UHFFFAOYSA-N 1-aminocyclopentan-1-ol;hydrochloride Chemical compound Cl.NC1(O)CCCC1 MTHQFRHZRCYLOP-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical compound CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- MOGQNVSKBCVIPW-UHFFFAOYSA-N 1-methylpyrazol-3-amine Chemical compound CN1C=CC(N)=N1 MOGQNVSKBCVIPW-UHFFFAOYSA-N 0.000 description 1
- MZMNEDXVUJLQAF-SFYZADRCSA-N 1-o-tert-butyl 2-o-methyl (2s,4r)-4-hydroxypyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)[C@@H]1C[C@@H](O)CN1C(=O)OC(C)(C)C MZMNEDXVUJLQAF-SFYZADRCSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- BCJUMGSHTLYECD-UHFFFAOYSA-N 2,2,2-trifluoro-1-piperidin-1-ylethanone Chemical compound FC(F)(F)C(=O)N1CCCCC1 BCJUMGSHTLYECD-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- HXWLJBVVXXBZCM-UHFFFAOYSA-N 2,3-dihydroxypropyl nitrate Chemical compound OCC(O)CO[N+]([O-])=O HXWLJBVVXXBZCM-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- MVAXDKDOPWPFML-UHFFFAOYSA-N 2-(dimethylamino)acetyl chloride;hydrochloride Chemical compound [Cl-].C[NH+](C)CC(Cl)=O MVAXDKDOPWPFML-UHFFFAOYSA-N 0.000 description 1
- NZAWVUCFCXYXMA-FJXQXJEOSA-N 2-[(3s)-oxolan-3-yl]oxypyridin-3-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NC1=CC=CN=C1O[C@@H]1COCC1 NZAWVUCFCXYXMA-FJXQXJEOSA-N 0.000 description 1
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
- MEBFFOKESLAUSJ-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxyacetaldehyde Chemical compound CC(C)(C)[Si](C)(C)OCC=O MEBFFOKESLAUSJ-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- IIDUNAVOCYMUFB-UHFFFAOYSA-N 2-amino-5-fluorophenol Chemical compound NC1=CC=C(F)C=C1O IIDUNAVOCYMUFB-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- OBWDPLOCTVOTMA-UHFFFAOYSA-N 2-fluoro-1-nitro-4-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC=C(C(F)(F)F)C=C1F OBWDPLOCTVOTMA-UHFFFAOYSA-N 0.000 description 1
- WZMOWQCNPFDWPA-UHFFFAOYSA-N 2-fluoro-4-methyl-1-nitrobenzene Chemical compound CC1=CC=C([N+]([O-])=O)C(F)=C1 WZMOWQCNPFDWPA-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- HLTDBMHJSBSAOM-UHFFFAOYSA-N 2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CC=N1 HLTDBMHJSBSAOM-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- OZXCOGPRBUSXLE-UHFFFAOYSA-N 3-fluoro-4-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=C(C#N)C=C1F OZXCOGPRBUSXLE-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- JRCLEGSGUUSEGZ-UHFFFAOYSA-N 3-nitro-2-(oxan-4-yloxy)pyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1OC1CCOCC1 JRCLEGSGUUSEGZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- VKXIOAZUPILOTF-CYBMUJFWSA-N 4-[2-[(3r)-1-(2,2-difluoroethyl)piperidin-3-yl]oxy-4-fluoroanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCCN(CC(F)F)C1 VKXIOAZUPILOTF-CYBMUJFWSA-N 0.000 description 1
- QSKHQLXYJNBYIK-CQSZACIVSA-N 4-[2-[(3r)-1-acetylpiperidin-3-yl]oxy-4-fluoroanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C1N(C(=O)C)CCC[C@H]1OC1=CC(F)=CC=C1NC1=NC=NC2=C1C(C)=C(C(O)=O)S2 QSKHQLXYJNBYIK-CQSZACIVSA-N 0.000 description 1
- HBVXAOKNEBODSR-ZDUSSCGKSA-N 4-[2-[(3s)-1-acetylpyrrolidin-3-yl]oxy-4-fluoroanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C1N(C(=O)C)CC[C@@H]1OC1=CC(F)=CC=C1NC1=NC=NC2=C1C(C)=C(C(N)=O)S2 HBVXAOKNEBODSR-ZDUSSCGKSA-N 0.000 description 1
- KJXWXLGLUPEYCR-UHFFFAOYSA-N 4-[4-fluoro-2-(oxan-4-yloxy)anilino]-5-methyl-n-[(4-methylmorpholin-2-yl)methyl]thieno[2,3-d]pyrimidine-6-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1N(C)CCOC1CNC(=O)C1=C(C)C2=C(NC=3C(=CC(F)=CC=3)OC3CCOCC3)N=CN=C2S1 KJXWXLGLUPEYCR-UHFFFAOYSA-N 0.000 description 1
- WMBKFTBHUCZSKS-YHBSKVLESA-N 4-[4-fluoro-2-(oxan-4-yloxy)anilino]-n-[(3s)-3-hydroxy-1-methylpiperidin-4-yl]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide;hydrochloride Chemical compound Cl.O[C@H]1CN(C)CCC1NC(=O)C1=C(C)C2=C(NC=3C(=CC(F)=CC=3)OC3CCOCC3)N=CN=C2S1 WMBKFTBHUCZSKS-YHBSKVLESA-N 0.000 description 1
- IWXUCINGGFYGNV-NSHDSACASA-N 4-[4-fluoro-2-[(3S)-pyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound FC1=CC(=C(C=C1)NC=1C2=C(N=CN=1)SC(=C2C)C(=O)O)O[C@@H]1CNCC1 IWXUCINGGFYGNV-NSHDSACASA-N 0.000 description 1
- WSSAQSZXJILCPN-CQSZACIVSA-N 4-[4-fluoro-2-[(3r)-1-(1,2,4-oxadiazol-3-ylmethyl)piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C([C@H](C1)OC2=CC(F)=CC=C2NC=2N=CN=C3SC(=C(C=23)C)C(N)=O)CCN1CC=1N=CON=1 WSSAQSZXJILCPN-CQSZACIVSA-N 0.000 description 1
- BEYCMPVDBWSHDX-CQSZACIVSA-N 4-[4-fluoro-2-[(3r)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCN(C(=O)OC(C)(C)C)C1 BEYCMPVDBWSHDX-CQSZACIVSA-N 0.000 description 1
- UGLWAGLKGGYJSV-CYBMUJFWSA-N 4-[4-fluoro-2-[(3r)-1-methylpiperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C1N(C)CCC[C@H]1OC1=CC(F)=CC=C1NC1=NC=NC2=C1C(C)=C(C(N)=O)S2 UGLWAGLKGGYJSV-CYBMUJFWSA-N 0.000 description 1
- GOLYWZDVGKYQBR-CYBMUJFWSA-N 4-[4-fluoro-2-[(3r)-1-methylsulfonylpiperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCCN(S(C)(=O)=O)C1 GOLYWZDVGKYQBR-CYBMUJFWSA-N 0.000 description 1
- UPPGBAFPCOAXNG-CYBMUJFWSA-N 4-[4-fluoro-2-[(3r)-1-methylsulfonylpiperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCCN(S(C)(=O)=O)C1 UPPGBAFPCOAXNG-CYBMUJFWSA-N 0.000 description 1
- IUTGZVTYASHFJX-GFCCVEGCSA-N 4-[4-fluoro-2-[(3r)-1-methylsulfonylpyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCN(S(C)(=O)=O)C1 IUTGZVTYASHFJX-GFCCVEGCSA-N 0.000 description 1
- ALPPDPLXYIGCSW-GOSISDBHSA-N 4-[4-fluoro-2-[(3r)-oxan-3-yl]oxyanilino]-5-methyl-n-(1-methylpiperidin-4-yl)thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C1CN(C)CCC1NC(=O)C1=C(C)C2=C(NC=3C(=CC(F)=CC=3)O[C@H]3COCCC3)N=CN=C2S1 ALPPDPLXYIGCSW-GOSISDBHSA-N 0.000 description 1
- BEOABWFJCLCWDT-LJQANCHMSA-N 4-[4-fluoro-2-[(3r)-oxan-3-yl]oxyanilino]-5-methyl-n-(3-pyrrolidin-1-ylpropyl)thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(=O)NCCCN3CCCC3)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCCOC1 BEOABWFJCLCWDT-LJQANCHMSA-N 0.000 description 1
- JTNRNYLJUHRKQJ-GFCCVEGCSA-N 4-[4-fluoro-2-[(3r)-oxolan-3-yl]oxyanilino]-5-methyl-n-methylsulfonylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(=O)NS(C)(=O)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCOC1 JTNRNYLJUHRKQJ-GFCCVEGCSA-N 0.000 description 1
- TZPWHOGGSADFPG-GFCCVEGCSA-N 4-[4-fluoro-2-[(3r)-oxolan-3-yl]oxyanilino]-n-methoxy-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(=O)NOC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCOC1 TZPWHOGGSADFPG-GFCCVEGCSA-N 0.000 description 1
- NIFDZTVCNWTGNA-AWEZNQCLSA-N 4-[4-fluoro-2-[(3s)-1-(2-hydroxyethyl)piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCN(CCO)C1 NIFDZTVCNWTGNA-AWEZNQCLSA-N 0.000 description 1
- LNNZEIFYTIOHNS-HNNXBMFYSA-N 4-[4-fluoro-2-[(3s)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCN(C(=O)OC(C)(C)C)C1 LNNZEIFYTIOHNS-HNNXBMFYSA-N 0.000 description 1
- UPPGBAFPCOAXNG-ZDUSSCGKSA-N 4-[4-fluoro-2-[(3s)-1-methylsulfonylpiperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCN(S(C)(=O)=O)C1 UPPGBAFPCOAXNG-ZDUSSCGKSA-N 0.000 description 1
- ADRZTEXTCJHQJT-KRWDZBQOSA-N 4-[4-fluoro-2-[(3s)-oxolan-3-yl]oxyanilino]-5-methyl-n-(1-methylpiperidin-4-yl)thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C1CN(C)CCC1NC(=O)C1=C(C)C2=C(NC=3C(=CC(F)=CC=3)O[C@@H]3COCC3)N=CN=C2S1 ADRZTEXTCJHQJT-KRWDZBQOSA-N 0.000 description 1
- XBEGHMWOHVVFAW-ZDUSSCGKSA-N 4-[4-fluoro-2-[(3s)-piperidin-3-yl]oxyanilino]-n,5-dimethylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(=O)NC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCNC1 XBEGHMWOHVVFAW-ZDUSSCGKSA-N 0.000 description 1
- RSJBDWOYKCPWNH-GJZGRUSLSA-N 4-[4-fluoro-2-[(3s,5s)-5-(hydroxymethyl)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(C)=C(C(O)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1C[C@@H](CO)N(C(=O)OC(C)(C)C)C1 RSJBDWOYKCPWNH-GJZGRUSLSA-N 0.000 description 1
- ZQJBEONTNXUMJF-STQMWFEESA-N 4-[4-fluoro-2-[(3s,5s)-5-(hydroxymethyl)-1-methylsulfonylpyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1C[C@@H](CO)N(S(C)(=O)=O)C1 ZQJBEONTNXUMJF-STQMWFEESA-N 0.000 description 1
- NHJVWHKYMAAZKI-RYUDHWBXSA-N 4-[4-fluoro-2-[(3s,5s)-5-(hydroxymethyl)pyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CN[C@H](CO)C1 NHJVWHKYMAAZKI-RYUDHWBXSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- PTCPUGKKWNMITF-UHFFFAOYSA-N 4-chloro-2-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1F PTCPUGKKWNMITF-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- GUHWVBWAJUDPGE-JTQLQIEISA-N 5-methyl-4-[[2-[(3s)-oxolan-3-yl]oxypyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=CN=C1O[C@H]1CCOC1 GUHWVBWAJUDPGE-JTQLQIEISA-N 0.000 description 1
- RTWPFCVBBCHLAH-UHFFFAOYSA-N 5-methyl-n-(3-methylsulfinylpropyl)-4-[[2-(oxan-4-yloxy)pyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(=O)NCCCS(C)=O)SC2=NC=NC=1NC1=CC=CN=C1OC1CCOCC1 RTWPFCVBBCHLAH-UHFFFAOYSA-N 0.000 description 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- GEPMAHVDJHFBJI-UHFFFAOYSA-N 7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(O)CN(CCO)C GEPMAHVDJHFBJI-UHFFFAOYSA-N 0.000 description 1
- HAMRAAJSLGYSDM-UHFFFAOYSA-N 7-azabicyclo[4.2.0]octa-1,3,5,7-tetraene Chemical compound C1=CC=C2C=NC2=C1 HAMRAAJSLGYSDM-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000027896 Aortic valve disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- GBCNHJYDOBCPEW-UHFFFAOYSA-N C(CCCCC)[SiH](N[SiH3])C.[Li] Chemical compound C(CCCCC)[SiH](N[SiH3])C.[Li] GBCNHJYDOBCPEW-UHFFFAOYSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- YARVKQIFVDMTAT-UHFFFAOYSA-N C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.P(O)(O)(O)=O Chemical compound C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.P(O)(O)(O)=O YARVKQIFVDMTAT-UHFFFAOYSA-N 0.000 description 1
- PIPVSJXMLXZKDK-ROUUACIJSA-N CC(C)(C)OC(N(C1)[C@H](CO)C[C@@H]1Oc(cc(cc1)F)c1Nc1c(c(C)c(C(OC)=O)[s]2)c2ncn1)=C Chemical compound CC(C)(C)OC(N(C1)[C@H](CO)C[C@@H]1Oc(cc(cc1)F)c1Nc1c(c(C)c(C(OC)=O)[s]2)c2ncn1)=C PIPVSJXMLXZKDK-ROUUACIJSA-N 0.000 description 1
- QTWLFSLDPLNKSZ-ZDUSSCGKSA-N CC(C)(C)OC(N(CCC1)C[C@H]1Oc(cc(C)cc1)c1[N+]([O-])=O)=O Chemical compound CC(C)(C)OC(N(CCC1)C[C@H]1Oc(cc(C)cc1)c1[N+]([O-])=O)=O QTWLFSLDPLNKSZ-ZDUSSCGKSA-N 0.000 description 1
- FNQYBWVPWPAKOQ-UHFFFAOYSA-N CC(c1ccc[n]1C)I Chemical compound CC(c1ccc[n]1C)I FNQYBWVPWPAKOQ-UHFFFAOYSA-N 0.000 description 1
- HWOGMRKXZXBILU-UHFFFAOYSA-N CC1=C(C(NCCCN(C)C)=O)SC2NC=NC(Nc(ccc(F)c3)c3OC3COCCC3)=C12 Chemical compound CC1=C(C(NCCCN(C)C)=O)SC2NC=NC(Nc(ccc(F)c3)c3OC3COCCC3)=C12 HWOGMRKXZXBILU-UHFFFAOYSA-N 0.000 description 1
- MPOJVYPYDFRBJD-AWEZNQCLSA-N CC1=C(SC2=NC=NC(=C12)NC3=C(N=CC=C3)O[C@H]4CCCN(C4)C(C)(C)C)C(=O)N Chemical compound CC1=C(SC2=NC=NC(=C12)NC3=C(N=CC=C3)O[C@H]4CCCN(C4)C(C)(C)C)C(=O)N MPOJVYPYDFRBJD-AWEZNQCLSA-N 0.000 description 1
- OVRKATYHWPCGPZ-UHFFFAOYSA-N CC1CCOCC1 Chemical compound CC1CCOCC1 OVRKATYHWPCGPZ-UHFFFAOYSA-N 0.000 description 1
- CGZDWVZMOMDGBN-UHFFFAOYSA-N CCc1ncc[s]1 Chemical compound CCc1ncc[s]1 CGZDWVZMOMDGBN-UHFFFAOYSA-N 0.000 description 1
- FDIQYJUJCHGPCF-UHFFFAOYSA-N COCC(N(CC(C1)Oc(cc(cc2)F)c2N2)C1c1c(C(O)=O)[s]c3ncnc2c13)=O Chemical compound COCC(N(CC(C1)Oc(cc(cc2)F)c2N2)C1c1c(C(O)=O)[s]c3ncnc2c13)=O FDIQYJUJCHGPCF-UHFFFAOYSA-N 0.000 description 1
- YODZJOWNRUXCBQ-UHFFFAOYSA-N COCC(N(CC(C1)Oc(cc(cc2)F)c2N2)C1c1c(C(OC)=O)[s]c3c1c2ncn3)=O Chemical compound COCC(N(CC(C1)Oc(cc(cc2)F)c2N2)C1c1c(C(OC)=O)[s]c3c1c2ncn3)=O YODZJOWNRUXCBQ-UHFFFAOYSA-N 0.000 description 1
- VZXBLWAFIVFFNN-UHFFFAOYSA-N CS(=O)(=O)OS(=O)(=O)CC1CCNC1 Chemical compound CS(=O)(=O)OS(=O)(=O)CC1CCNC1 VZXBLWAFIVFFNN-UHFFFAOYSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- ALPPDPLXYIGCSW-UHFFFAOYSA-N Cc1c(C(NC2CCN(C)CC2)=O)[s]c2ncnc(Nc(ccc(F)c3)c3OC3COCCC3)c12 Chemical compound Cc1c(C(NC2CCN(C)CC2)=O)[s]c2ncnc(Nc(ccc(F)c3)c3OC3COCCC3)c12 ALPPDPLXYIGCSW-UHFFFAOYSA-N 0.000 description 1
- XCYAYQIJZCTSPD-UHFFFAOYSA-N Cc1c(C(NCCCN(C)C)=O)[s]c2ncnc(Nc3cccnc3OCC3COCC3)c12 Chemical compound Cc1c(C(NCCCN(C)C)=O)[s]c2ncnc(Nc3cccnc3OCC3COCC3)c12 XCYAYQIJZCTSPD-UHFFFAOYSA-N 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 208000032780 Diabetic arthropathy Diseases 0.000 description 1
- 206010012645 Diabetic autonomic neuropathy Diseases 0.000 description 1
- 208000002230 Diabetic coma Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012665 Diabetic gangrene Diseases 0.000 description 1
- 206010012676 Diabetic mononeuropathy Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 208000013600 Diabetic vascular disease Diseases 0.000 description 1
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 description 1
- 108050004099 Diacylglycerol O-acyltransferase 1 Proteins 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 206010014935 Enzyme abnormality Diseases 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 206010015278 Erythrodermic psoriasis Diseases 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102000005233 Eukaryotic Initiation Factor-4E Human genes 0.000 description 1
- 108060002636 Eukaryotic Initiation Factor-4E Proteins 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 102000017013 Heterogeneous Nuclear Ribonucleoprotein A1 Human genes 0.000 description 1
- 108010014594 Heterogeneous Nuclear Ribonucleoprotein A1 Proteins 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101500028620 Homo sapiens Motilin-associated peptide Proteins 0.000 description 1
- 108010084048 Human Isophane Insulin Proteins 0.000 description 1
- 102000005561 Human Isophane Insulin Human genes 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010021000 Hypoglycaemic coma Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010073961 Insulin Aspart Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108010092217 Long-Acting Insulin Chemical class 0.000 description 1
- 229940100066 Long-acting insulin Drugs 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101150018665 MAPK3 gene Proteins 0.000 description 1
- 101150024075 Mapk1 gene Proteins 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 102000044589 Mitogen-Activated Protein Kinase 1 Human genes 0.000 description 1
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 201000000023 Osteosclerosis Diseases 0.000 description 1
- 208000031964 Other metabolic disease Diseases 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 108010026951 Short-Acting Insulin Chemical class 0.000 description 1
- 229940123958 Short-acting insulin Drugs 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005279 Status Asthmaticus Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 108010061168 Ultralente Insulin Proteins 0.000 description 1
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046742 Urticaria contact Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZGLWUFXXJGIQRT-GJZGRUSLSA-N [(2s,4s)-4-[2-[(6-carbamoyl-5-methylthieno[2,3-d]pyrimidin-4-yl)amino]-5-fluorophenoxy]-1-methylsulfonylpyrrolidin-2-yl]methyl acetate Chemical compound C1N(S(C)(=O)=O)[C@H](COC(=O)C)C[C@@H]1OC1=CC(F)=CC=C1NC1=NC=NC2=C1C(C)=C(C(N)=O)S2 ZGLWUFXXJGIQRT-GJZGRUSLSA-N 0.000 description 1
- QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 description 1
- IKWTVSLWAPBBKU-UHFFFAOYSA-N a1010_sial Chemical compound O=[As]O[As]=O IKWTVSLWAPBBKU-UHFFFAOYSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229960001683 abetimus Drugs 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 229960003526 acipimox Drugs 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002255 antigout agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910000413 arsenic oxide Inorganic materials 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 230000006470 autoimmune attack Effects 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- UYRCOTSOPWOSJK-JXTBTVDRSA-N bradykinin antagonist Chemical compound C1C2=CC=CC=C2CC1[C@@H](NC(=O)C(CO)NC(=O)C(NC(=O)CNC(=O)[C@H]1N(C[C@H](O)C1)C(=O)C1N(CCC1)C(=O)C(CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=N)CCCCCCC(=N)N[C@H](CCCNC(N)=N)C(=O)NC(CCCNC(N)=N)C(=O)N1C(CCC1)C(=O)N1[C@@H](C[C@@H](O)C1)C(=O)NCC(=O)NC(C1CC2=CC=CC=C2C1)C(=O)NC(CO)C(=O)N[C@H](C1CC2=CC=CC=C2C1)C(=O)N1C2CCCCC2CC1C(=O)NC(CCCNC(N)=N)C(O)=O)C1CC2=CC=CC=C2C1)C(=O)N1C2CCCCC2CC1C(=O)NC(CCCNC(=N)N)C(O)=O UYRCOTSOPWOSJK-JXTBTVDRSA-N 0.000 description 1
- 239000003152 bradykinin antagonist Substances 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229960003362 carbutamide Drugs 0.000 description 1
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N chlorthalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- OJBNDADUQQUPLL-UHFFFAOYSA-N colestipol hydrochloride Chemical compound Cl.ClCC1CO1.NCCNCCN OJBNDADUQQUPLL-UHFFFAOYSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 230000024415 compound eye development Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CSMFSDCPJHNZRY-UHFFFAOYSA-M decyl sulfate Chemical compound CCCCCCCCCCOS([O-])(=O)=O CSMFSDCPJHNZRY-UHFFFAOYSA-M 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960002783 dexketoprofen Drugs 0.000 description 1
- DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 201000002342 diabetic polyneuropathy Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical group CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical compound CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Chemical group C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- DFBKLUNHFCTMDC-GKRDHZSOSA-N endrin Chemical compound C([C@@H]1[C@H]2[C@@]3(Cl)C(Cl)=C([C@]([C@H]22)(Cl)C3(Cl)Cl)Cl)[C@@H]2[C@H]2[C@@H]1O2 DFBKLUNHFCTMDC-GKRDHZSOSA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- ZRSDQBKGDNPFLT-UHFFFAOYSA-N ethanol;oxolane Chemical compound CCO.C1CCOC1 ZRSDQBKGDNPFLT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- RTDOEPBNFMONDD-CYBMUJFWSA-N ethyl 4-[4-fluoro-2-[(3r)-oxolan-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OCC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCOC1 RTDOEPBNFMONDD-CYBMUJFWSA-N 0.000 description 1
- QOWHUDHNSZZLLZ-KRWDZBQOSA-N ethyl 4-[4-fluoro-2-[(3s)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OCC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCN(C(=O)OC(C)(C)C)C1 QOWHUDHNSZZLLZ-KRWDZBQOSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960002849 glucosamine sulfate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940015045 gold sodium thiomalate Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- IDINUJSAMVOPCM-UHFFFAOYSA-N gusperimus Chemical compound NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 102000056485 human MKNK2 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 108010071377 human long-acting insulin Proteins 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- RGZRSLKIOCHTSI-UHFFFAOYSA-N hydron;n-methylhydroxylamine;chloride Chemical compound Cl.CNO RGZRSLKIOCHTSI-UHFFFAOYSA-N 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 229960004717 insulin aspart Drugs 0.000 description 1
- 229960002068 insulin lispro Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960001120 levocabastine Drugs 0.000 description 1
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229960003134 mepindolol Drugs 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- QEWMKBATHJUVRG-OAHLLOKOSA-N methyl 4-[2-[(3r)-1-acetylpiperidin-3-yl]oxy-4-fluoroanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCCN(C(C)=O)C1 QEWMKBATHJUVRG-OAHLLOKOSA-N 0.000 description 1
- XKCMRXPGXSSUFH-UHFFFAOYSA-N methyl 4-[2-[1-[2-(dimethylamino)acetyl]pyrrolidin-3-yl]oxy-4-fluoroanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1OC1CCN(C(=O)CN(C)C)C1 XKCMRXPGXSSUFH-UHFFFAOYSA-N 0.000 description 1
- IIAYWQWHBGJLNP-AWEZNQCLSA-N methyl 4-[4-cyano-2-[(3s)-1-(2,2,2-trifluoroacetyl)piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(C#N)C=C1O[C@H]1CCCN(C(=O)C(F)(F)F)C1 IIAYWQWHBGJLNP-AWEZNQCLSA-N 0.000 description 1
- NFJYPZIPHVMIHY-UHFFFAOYSA-N methyl 4-[4-fluoro-2-(oxan-4-yloxy)anilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1OC1CCOCC1 NFJYPZIPHVMIHY-UHFFFAOYSA-N 0.000 description 1
- GLBQHCWGCWWYRC-MRXNPFEDSA-N methyl 4-[4-fluoro-2-[(3r)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCCN(C(=O)OC(C)(C)C)C1 GLBQHCWGCWWYRC-MRXNPFEDSA-N 0.000 description 1
- ZDNUFVYIQGEAHD-CQSZACIVSA-N methyl 4-[4-fluoro-2-[(3r)-1-methylsulfonylpiperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCCN(S(C)(=O)=O)C1 ZDNUFVYIQGEAHD-CQSZACIVSA-N 0.000 description 1
- QYNHCHNNFMWPKS-CYBMUJFWSA-N methyl 4-[4-fluoro-2-[(3r)-1-methylsulfonylpyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCN(S(C)(=O)=O)C1 QYNHCHNNFMWPKS-CYBMUJFWSA-N 0.000 description 1
- MWTKOCBVDHTQKP-CYBMUJFWSA-N methyl 4-[4-fluoro-2-[(3r)-oxan-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCCOC1 MWTKOCBVDHTQKP-CYBMUJFWSA-N 0.000 description 1
- BOXVQRROQROSHA-GFCCVEGCSA-N methyl 4-[4-fluoro-2-[(3r)-oxolan-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCOC1 BOXVQRROQROSHA-GFCCVEGCSA-N 0.000 description 1
- LZCONRMFWONWLA-HNNXBMFYSA-N methyl 4-[4-fluoro-2-[(3s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCN(C(=O)OC(C)(C)C)C1 LZCONRMFWONWLA-HNNXBMFYSA-N 0.000 description 1
- ZDNUFVYIQGEAHD-AWEZNQCLSA-N methyl 4-[4-fluoro-2-[(3s)-1-methylsulfonylpiperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCN(S(C)(=O)=O)C1 ZDNUFVYIQGEAHD-AWEZNQCLSA-N 0.000 description 1
- PQBOBUIJNJKQHG-INIZCTEOSA-N methyl 4-[4-fluoro-2-[(3s)-1-propan-2-yloxycarbonylpiperidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCN(C(=O)OC(C)C)C1 PQBOBUIJNJKQHG-INIZCTEOSA-N 0.000 description 1
- MWTKOCBVDHTQKP-ZDUSSCGKSA-N methyl 4-[4-fluoro-2-[(3s)-oxan-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCOC1 MWTKOCBVDHTQKP-ZDUSSCGKSA-N 0.000 description 1
- MXCKYLJKOUWCMM-HOTGVXAUSA-N methyl 4-[4-fluoro-2-[(3s,5s)-5-(hydroxymethyl)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1C[C@@H](CO)N(C(=O)OC(C)(C)C)C1 MXCKYLJKOUWCMM-HOTGVXAUSA-N 0.000 description 1
- RCLZHUMWKCDKFV-UHFFFAOYSA-N methyl 4-[4-fluoro-2-[1-(2-methoxyacetyl)pyrrolidin-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C1N(C(=O)COC)CCC1OC1=CC(F)=CC=C1NC1=NC=NC2=C1C(C)=C(C(=O)OC)S2 RCLZHUMWKCDKFV-UHFFFAOYSA-N 0.000 description 1
- COSIUDOWUSMJAT-AWEZNQCLSA-N methyl 5-methyl-4-[4-methyl-2-[(3s)-1-(2,2,2-trifluoroacetyl)piperidin-3-yl]oxyanilino]thieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=C(C)C=C1O[C@H]1CCCN(C(=O)C(F)(F)F)C1 COSIUDOWUSMJAT-AWEZNQCLSA-N 0.000 description 1
- PEKOLQZWOWIRIB-GFCCVEGCSA-N methyl 5-methyl-4-[[2-[(3r)-oxan-3-yl]oxypyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=CN=C1O[C@@H]1CCCOC1 PEKOLQZWOWIRIB-GFCCVEGCSA-N 0.000 description 1
- CPLAERIISMZLSP-HNNXBMFYSA-N methyl 5-methyl-4-[[2-[(3s)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]oxypyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(C)=C(C(=O)OC)SC2=NC=NC=1NC1=CC=CN=C1O[C@H]1CCCN(C(=O)OC(C)(C)C)C1 CPLAERIISMZLSP-HNNXBMFYSA-N 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960002902 moxaverine Drugs 0.000 description 1
- MYCMTMIGRXJNSO-UHFFFAOYSA-N moxaverine Chemical compound N=1C(CC)=CC2=CC(OC)=C(OC)C=C2C=1CC1=CC=CC=C1 MYCMTMIGRXJNSO-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZOSRDZFVOYEZFU-UHFFFAOYSA-N n-(3-amino-2-hydroxypropyl)-4-[4-fluoro-2-(oxan-4-yloxy)anilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(=O)NCC(O)CN)SC2=NC=NC=1NC1=CC=C(F)C=C1OC1CCOCC1 ZOSRDZFVOYEZFU-UHFFFAOYSA-N 0.000 description 1
- PDFYCMOIRNNWFC-UHFFFAOYSA-N n-[3-(dimethylamino)-2-hydroxypropyl]-4-[4-fluoro-2-(oxan-4-yloxy)anilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide;hydrochloride Chemical compound Cl.C=12C(C)=C(C(=O)NCC(O)CN(C)C)SC2=NC=NC=1NC1=CC=C(F)C=C1OC1CCOCC1 PDFYCMOIRNNWFC-UHFFFAOYSA-N 0.000 description 1
- JEEJNOQWIZNQHN-QGZVFWFLSA-N n-[3-(dimethylamino)propyl]-4-[4-fluoro-2-[(3r)-oxan-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(=O)NCCCN(C)C)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCCOC1 JEEJNOQWIZNQHN-QGZVFWFLSA-N 0.000 description 1
- LRHDUHZSPAJSHL-MRXNPFEDSA-N n-[3-(dimethylamino)propyl]-4-[4-fluoro-2-[(3r)-oxolan-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(=O)NCCCN(C)C)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCOC1 LRHDUHZSPAJSHL-MRXNPFEDSA-N 0.000 description 1
- JEEJNOQWIZNQHN-KRWDZBQOSA-N n-[3-(dimethylamino)propyl]-4-[4-fluoro-2-[(3s)-oxan-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(=O)NCCCN(C)C)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCOC1 JEEJNOQWIZNQHN-KRWDZBQOSA-N 0.000 description 1
- LRHDUHZSPAJSHL-INIZCTEOSA-N n-[3-(dimethylamino)propyl]-4-[4-fluoro-2-[(3s)-oxolan-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(=O)NCCCN(C)C)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCOC1 LRHDUHZSPAJSHL-INIZCTEOSA-N 0.000 description 1
- UGOMRZJYCMJYCG-HNNXBMFYSA-N n-[3-(dimethylamino)propyl]-5-methyl-4-[[2-[(3s)-oxolan-3-yl]oxypyridin-3-yl]amino]thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(=O)NCCCN(C)C)SC2=NC=NC=1NC1=CC=CN=C1O[C@H]1CCOC1 UGOMRZJYCMJYCG-HNNXBMFYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- MGCJFHPNTFDPIW-GFCCVEGCSA-N n-cyano-4-[4-fluoro-2-[(3r)-oxolan-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(=O)NC#N)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCOC1 MGCJFHPNTFDPIW-GFCCVEGCSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229960000619 nebivolol Drugs 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 229960001085 piretanide Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 239000003600 podophyllotoxin derivative Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 201000002765 pyometritis Diseases 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- QPMSJEFZULFYTB-UHFFFAOYSA-N pyrrolidin-1-ium-3-ol;chloride Chemical compound Cl.OC1CCNC1 QPMSJEFZULFYTB-UHFFFAOYSA-N 0.000 description 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- RWRDJVNMSZYMDV-UHFFFAOYSA-L radium chloride Chemical compound [Cl-].[Cl-].[Ra+2] RWRDJVNMSZYMDV-UHFFFAOYSA-L 0.000 description 1
- 229910001630 radium chloride Inorganic materials 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000015766 regulation of tumor necrosis factor biosynthetic process Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229950009213 rubitecan Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 230000006354 stress signaling Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- CSMFSDCPJHNZRY-UHFFFAOYSA-N sulfuric acid monodecyl ester Natural products CCCCCCCCCCOS(O)(=O)=O CSMFSDCPJHNZRY-UHFFFAOYSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003658 talinolol Drugs 0.000 description 1
- MXFWWQICDIZSOA-UHFFFAOYSA-N talinolol Chemical compound C1=CC(OCC(O)CNC(C)(C)C)=CC=C1NC(=O)NC1CCCCC1 MXFWWQICDIZSOA-UHFFFAOYSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- KOJDMQFXZVNIIR-IRXDYDNUSA-N tert-butyl (2s,4s)-2-(acetyloxymethyl)-4-[2-[(6-carbamoyl-5-methylthieno[2,3-d]pyrimidin-4-yl)amino]-5-fluorophenoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)[C@H](COC(=O)C)C[C@@H]1OC1=CC(F)=CC=C1NC1=NC=NC2=C1C(C)=C(C(N)=O)S2 KOJDMQFXZVNIIR-IRXDYDNUSA-N 0.000 description 1
- HJHGMKIWKHIPDB-GJZGRUSLSA-N tert-butyl (2s,4s)-4-[2-[(6-carbamoyl-5-methylthieno[2,3-d]pyrimidin-4-yl)amino]-5-fluorophenoxy]-2-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1C[C@@H](CO)N(C(=O)OC(C)(C)C)C1 HJHGMKIWKHIPDB-GJZGRUSLSA-N 0.000 description 1
- IKHAWCDHYJWYHZ-OAHLLOKOSA-N tert-butyl (3r)-3-[2-[(6-carbamoyl-5-methylthieno[2,3-d]pyrimidin-4-yl)amino]-5-fluorophenoxy]piperidine-1-carboxylate Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@@H]1CCCN(C(=O)OC(C)(C)C)C1 IKHAWCDHYJWYHZ-OAHLLOKOSA-N 0.000 description 1
- APCBTRDHCDOPNY-SSDOTTSWSA-N tert-butyl (3r)-3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](O)C1 APCBTRDHCDOPNY-SSDOTTSWSA-N 0.000 description 1
- IKHAWCDHYJWYHZ-HNNXBMFYSA-N tert-butyl (3s)-3-[2-[(6-carbamoyl-5-methylthieno[2,3-d]pyrimidin-4-yl)amino]-5-fluorophenoxy]piperidine-1-carboxylate Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCCN(C(=O)OC(C)(C)C)C1 IKHAWCDHYJWYHZ-HNNXBMFYSA-N 0.000 description 1
- CXSBPAKAUZBNLQ-AWEZNQCLSA-N tert-butyl (3s)-3-[3-[(6-carbamoyl-5-methylthieno[2,3-d]pyrimidin-4-yl)amino]pyridin-2-yl]oxypiperidine-1-carboxylate Chemical compound C=12C(C)=C(C(N)=O)SC2=NC=NC=1NC1=CC=CN=C1O[C@H]1CCCN(C(=O)OC(C)(C)C)C1 CXSBPAKAUZBNLQ-AWEZNQCLSA-N 0.000 description 1
- KWQRKOSMSFLBTJ-QMMMGPOBSA-N tert-butyl (3s)-3-methylsulfonyloxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](OS(C)(=O)=O)C1 KWQRKOSMSFLBTJ-QMMMGPOBSA-N 0.000 description 1
- YVMDZMBHMXWMQN-UHFFFAOYSA-N tert-butyl 2-aminoazepane-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1C(CCCCC1)N YVMDZMBHMXWMQN-UHFFFAOYSA-N 0.000 description 1
- UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 1
- VWOQNCYMDPLDNT-ANYOKISRSA-N tert-butyl 4-[[4-[4-fluoro-2-[(3s)-oxolan-3-yl]oxyanilino]-5-methylthieno[2,3-d]pyrimidine-6-carbonyl]amino]azepane-1-carboxylate Chemical compound C=12C(C)=C(C(=O)NC3CCN(CCC3)C(=O)OC(C)(C)C)SC2=NC=NC=1NC1=CC=C(F)C=C1O[C@H]1CCOC1 VWOQNCYMDPLDNT-ANYOKISRSA-N 0.000 description 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229960000363 trapidil Drugs 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 229960001130 urapidil Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
さらに、本発明は、Mnk1(Mnk1aまたはMnK1b)および/もしくはMnk2(Mnk2aまたはMnk2b)またはさらにその変異体のキナーゼ活性の阻害により影響を受ける可能性のある疾患の予防および/または処置のための医薬組成物を製造するための本発明のチエノピリミジン化合物の使用に関する。特に、本発明は、代謝性疾患、例えば糖尿病、高脂血症および肥満、造血障害、神経変性疾患、腎障害、炎症性障害、およびがん、ならびにこれらに伴うこれらに続発する合併症および障害などの予防および/または治療のための医薬組成物の製造のための本発明のチエノピリミジン化合物の使用に関する。
本発明は、より具体的には、特に脂質および炭水化物代謝の代謝性疾患およびこれに伴う続発する合併症および障害の処置ならびに/または予防を対象とする。
脂質障害は、血漿脂質およびリポタンパク質のレベルおよび代謝の異常を引き起こす一連の状態を包含する。よって、高脂血症は、アテローム性動脈硬化症およびそれに続く血管疾患、例えば冠動脈心疾患などの発症に対する重要なリスクファクターを構成するので、特に臨床上の関連性がある。
糖尿病は、極めて障害性の疾患である。なぜなら、現在の一般的な抗糖尿病薬物は、高血糖および低血糖レベルの発生を完全に防止する程度まで十分に血糖レベルを制御することができないからである。範囲を超える血糖レベルは有毒であり、長期合併症、例えば網膜症、腎臓病、ニューロパシーおよび末梢血管性疾患を引き起こす。さらにまた、多数の関連する状態、例えば肥満、高血圧、心疾患および高脂血症なども存在し、糖尿病の患者はこれら疾患に対するリスクが実質的に高い。
肥満は、続発性疾患、例えば、心臓血管疾患、高血圧、糖尿病、高脂血症および死亡率増加のリスクの増加に関連している。糖尿病(インスリン抵抗性)および肥満は、いくつかの疾患との連鎖と定義される「メタボリックシンドローム」(またX症候群、インスリン耐性症候群、または死の四重奏とも呼ばれている)の一部である。これらは、同じ患者で発症することが多く、II型糖尿病および心臓血管疾患の発症の主要な危険因子である。脂質レベルおよびグルコースレベルの制御が、II型糖尿病、心疾患、および他のメタボリックシンドローム発症の処置に必要であることが示唆されている(例えば、Diabetes 48: 1836-1841, 1999; JAMA 288: 2209-2716, 2002を参照されたい)。
さらなる実施形態において、本発明の化合物および組成物は、以下のような脂質代謝の代謝性疾患(すなわち脂質障害)ならびにこれらに続発する合併症および障害の処置および/または予防に有用である:高コレステロール血症、家族性高コレステロール血症、フレドリックソン高リポタンパク質血症、高βリポタンパク質血症、高脂血症、低密度リポタンパク質型[LDL]高リポタンパク質血症、純粋高グリセリド血症、内因性高グリセリド血症、孤立性高コレステロール血症、孤立性高トリグリセリド血症、心臓血管疾患、例えば高血圧、虚血、拡張蛇行静脈、網膜静脈閉塞、アテローム性動脈硬化症、狭心症(angina pectoris)、心筋梗塞、狭心症(stenocardia)、肺高血圧症、うっ血性心不全、糸球体症、尿細管間質性障害、腎不全、血管狭窄症、または脳血管障害、例えば脳卒中など。
本発明のさらなる実施形態において、本発明の化合物および組成物は、以下のような造血障害ならびにこれらに続発する合併症および障害の処置および/または予防に有用である:急性骨髄性白血病(AML)、ホジキン病、非ホジキンリンパ腫;造血性疾患、急性非リンパ性白血病(ANLL)、骨髄増殖性疾患、急性前骨髄球性白血病(APL)、急性骨髄単球性白血病(AMMoL)、多発性骨髄腫、真性赤血球増加症、リンパ腫、急性リンパ性白血病(ALL)、慢性リンパ球性白血病(CCL)、ウィルムス腫瘍、またはユーイング肉腫。
本発明のさらなる実施形態において、本発明の化合物および組成物は,以下のようながんならびに続発性合併症および障害の処置および/または予防に有用である:上部消化管のがん、膵臓癌、乳がん、大腸がん、卵巣癌、頚癌、子宮内膜がん、脳腫瘍、精巣がん、喉頭癌、骨癌、前立腺がん、網膜芽腫、肝臓癌、肺がん、神経芽細胞腫、腎臓癌、甲状腺癌、食道がん、軟部組織肉腫、皮膚がん、骨肉腫、横紋筋肉腫、膀胱がん、転移性がん、カヘキシー、または疼痛。
さらに、本発明は、サイトカイン関連疾患の予防および/または治療のための医薬組成物を製造するためのチエノピリミジン化合物の使用に関する。
アレルギー性および炎症性疾患、例えば急性または慢性炎症、慢性炎症性関節炎、関節リウマチ、乾癬、COPD、炎症性腸疾患、喘息および敗血症性ショックならびにこれらに伴うこれらに続発する合併症および障害。
関節リウマチのような炎症性疾患、COPDのような炎症性肺疾患、炎症性腸疾患および乾癬は、3人に1人が生涯のうちに罹患する。これらの疾患は、多大な保健医療費を強要するだけでなく、多くの場合体を不自由にさせ、衰弱させる。
炎症は、以下のこれら炎症性疾患の一体化した病理発生プロセスであるが、現行の処置方針は複雑であり、一般的には、任意の一つの疾患に対して特異的である。現在のところ利用可能である現行の処置法の多くは、疾患の症状を処置するのみであり、根底にある炎症の原因を処置するものではない。
過剰なサイトカイン産生はさらに、以下を含めた疾患の発症の媒介または悪化に関係づけられる:軟骨または筋肉吸収、肺線維症、肝硬変、腎線維症、特定の慢性疾患、例えば悪性の疾患および後天性免疫不全症候群(AIDS)などに見られるカヘキシー、腫瘍侵襲性および腫瘍転移および多発性硬化症。これらの疾患の処置および/または予防もまた、本発明により想定されている。
さらに、本発明の組成物は、以下を含むが、これらだけには限らない自己免疫性疾患に関連する炎症の処置にも使用することができる:全身性エリテマトーデス、アジソン病、自己免疫性多腺性疾患(自己免疫性多腺性症候群としても知られている)、糸球体腎炎、関節リウマチ強皮症、慢性甲状腺炎、グレーブス病、自己免疫性胃炎、糖尿病、自己免疫性溶血性貧血、糸球体腎炎、関節リウマチ自己免疫性好中球減少、血小板減少症、アトピー性皮膚炎、慢性活動性肝炎、重症筋無力症、多発性硬化症、炎症性腸疾患、潰瘍性大腸炎、クローン病、乾癬、および移植片対宿主病。
歯周病もまた、局所的および全身的の両方において、サイトカイン産生で発生する。したがって、歯肉炎および歯周炎などの口周囲疾患におけるサイトカイン産生に関連する炎症を制御するための本発明の組成物の使用は、本発明の別の態様である。
最後に、本発明の組成物はまた、以下から選択される神経変性疾患の処置または予防にも使用することができる:アルツハイマー病、パーキンソン病、筋萎縮性側索硬化症、ハンチントン病、前頭側頭葉型痴呆、脊髄小脳変性症、レビー小体型認知症、脳虚血、または外傷性損傷、グルタミン酸神経毒性もしくは低酸素により引き起こされる神経変性疾患。
タンパク質キナーゼは、多くの細胞機能の調節に関与している重要な酵素である。キイロショウジョウバエのLK6−セリン/トレオニン−キナーゼ遺伝子は、微小管と会合することができる短命キナーゼとして記載されている(J. Cell Sci. 1997, 110(2): 209-219)。ショウジョウバエの複眼の発達についての遺伝子分析は、RASシグナル経路のモジュレーションにおける役割を示唆した(Genetics 2000 156(3): 1219-1230)。ショウジョウバエLK6−キナーゼに最も近いヒトホモログは、MAP−キナーゼ相互作用キナーゼ2(Mnk2、例えば変異体Mnk2aおよびMnk2b)およびMAP−キナーゼ相互作用キナーゼ1(Mnk1)およびその変異体である。これらのキナーゼは、大半が細胞形質に局在している。Mnkは、p42MAPキナーゼErk1およびErk2ならびにp38−MAPキナーゼによりリン酸化される。このリン酸化は、成長因子、ホルボールエステルおよびオンコジーン、例えばRasおよびMosなどに反応して、ストレスシグナル伝達分子およびサイトカインによってトリガーされる。Mnkタンパク質のリン酸化は、真核生物開始因子4E(elF4E)に対するこれらのキナーゼ活性を刺激する(EMBO J. 16: 1909-1920, 1997; Mol Cell Biol 19, 1871-1880, 1990; Mol Cell Biol 21, 743-754, 2001)。マウスにおけるMnk1およびMnk2の両遺伝子の同時破壊は、基礎および刺激eIF4Eリン酸化を減少させる(Mol Cell Biol 24, 6539-6549, 2004)。elF4Eのリン酸化の結果として、タンパク質翻訳が調節される(Mol Cell Biol 22: 5500-5511, 2001)。
WO03/037362は、ヒトMnk遺伝子、特にヒトMnk2遺伝子の変異体と、体重または熱発生の調節に関連した疾患との関連について開示している。ヒトMnk遺伝子、特にMnk2変異体は、以下のような疾患に関与していると推定される:例えば肥満、摂食障害、カヘキシー、真性糖尿病、高血圧症、冠動脈心疾患、高コレステロール血症、異脂肪血症、変形性関節炎、胆石、生殖器のがんおよび睡眠時無呼吸を含めた代謝性疾患、およびROS防御に関連した疾患、例えば真性糖尿病およびがん。WO03/03762は、さらに、体重または熱発生の調節に関連した疾患の診断、予防または治療における、MAPキナーゼ−相互作用キナーゼ(Mnk)遺伝子ファミリーの核酸配列およびこれらをコード化しているアミノ酸配列の使用、ならびにこれらの配列またはMnk核酸もしくはポリペプチドのエフェクター、特にMnk阻害剤およびアクチベーターの使用について開示している。
WO02/103361は、特に2型真性糖尿病の処置に有用な薬理学的活性成分の同定のためのアッセイにおける、ヒトMAPキナーゼと相互作用するキナーゼ2aおよび2b(Mnk2aおよびMnk2b)の使用について記載している。さらに、WO02/103361はまた、Mnk2aまたはMnk2bの発現または活性のモジュレーションによる、インスリン耐性に関連した疾患の予防および/または治療についても開示している。ペプチドとは別に、模擬ペプチド、アミノ酸、アミノ酸類似体、ポリヌクレオチド、ポリヌクレオチド類似体、ヌクレオチドおよびヌクレオチド類似体、4−ヒドロキシ安息香酸メチルエステルが、ヒトMnk2タンパク質に結合する物質として記載されている。
さらに、Mnk1は、炎症促進性サイトカインの産生の調整に関与していることが示されている。Mnk1は、ケモカインRANTESの発現を促進する(Nikolcheva et al., J Clin Invest 110, 119-126, 2002)。RANTESは、単球、好酸球、好塩基球およびナチュラルキラー細胞の強力なケモトラクタントである。これは、Tリンパ球の増殖を活性化および誘発し、好塩基球の脱顆粒を媒介し、好酸球における呼吸バーストを誘発する(Conti and DiGioacchino, Allergy Asthma Proc 22(3): 133-7, 2001)。
TNFαは、AREにより調整される唯一のサイトカインではない。機能性AREはまた、いくつかのインターロイキン、インターフェロンおよびケモカインの転写において見出されている(Khabar, J Interf Cytokine Res 25: 1-10, 2005)。よってARE−結合タンパク質のMnk−媒介性リン酸化は、TNFαの生合成に加えてサイトカインの生合成を制御する潜在力を有する。
現在の証拠は、Mnkが、炎症性シグナル伝達の下流ターゲットならびに炎症反応の伝達物質であることを実証している。TNFα、RANTES、および潜在的に付加的なサイトカインの産生へのこれらの関与は、Mnkの阻害が、抗炎症治療的介入の戦略であることを示唆している。
さらなるMnk阻害剤が記載されている。例えばMnkキナーゼ阻害剤として、ピラゾロピリミジン化合物について記載しているWO06/066937、特定のチエノピリミジン化合物について記載しているWO06/136402、改質されたコア環を有するさらなるチエノピリミジン化合物について記載しているWO07/115822、ピロロピリミジンについて記載しているWO08/006547などの出願人の特許出願を参照されたい。
当技術分野で公知のチエノピリミジン化合物、例えば、出願人の特許出願であるWO06/136402およびWO2007/115822に開示された化合物とは対照的に、本発明のチエノピリミジン化合物は、いくつかの利点、すなわち、高い溶解度、安定した塩を形成する可能性、改善された代謝安定性、Mnk活性の生化学アッセイまたは細胞アッセイにおける強化または保持された活性、ならびに他のキナーゼに対する強化または保持された選択性を提供する。
WO06/136402およびWO07/115822で開示されたチエノピリミジン化合物は、Mnk酵素アッセイにおいて高い活性および極度に高い選択性を示すが、これらの化合物は、極めて低い溶解度を示し、ほとんどの場合、代謝的に不安定であり、結果として所望しない薬物動態学的特性が生じる。
以下の一般式(I)の化合物において、R4の位置への極性基の導入により、驚くほど多くの代謝安定化をもたらされ、これによって、本発明のチエノピリミジンがインビボの薬理学的用途に対して有用となることが、驚くことに判明した。
さらに、本出願に記載されている化合物はまた、改善された溶解性を示し、生化学アッセイおよび細胞アッセイにおいて強い阻害効力を有し、極めて選択的であり、結果として全体的に大きく改善された薬理学的特性が生じる。
他に特定されていない場合、本出願において述べられた任意のアルキル成分は、直鎖または分枝であってよい。
(式中、
Xは、CHまたはNであり、
R1は、H、ハロゲン、CN、CH3またはCF3であり、
R2は、
−SO2−(C1-3アルキル)、−CO−(C1-3アルキル)、−CO−(CH2)n−O−(C1-3アルキル)、−CO−(CH2)n−N(C1-3アルキル)2、C1-4アルキル、−(CH2)n−CF3、−(CH2)n−CHF2、−(CH2)n−OH、−(CH2)n−O−(C1-3アルキル)、−(CH2)n−CN、
炭素原子において、−CH2OH基で置換されていてもよく、
nは、1または2であり、
nは、1または2であり、
R3は、C1-2アルキル基であり、
R4は、−COOH、−CO2−(C1-3アルキル)、−CO2−(CH2)n−N(C1-3アルキル)2、−CONH2、−CO−NHR5、−CO−NH−(CH2)p−R6、−CO−NH−(CH2)m−R7、−CO−N(CH3)−(CH2)m−R7、CO−N(CH3)−(CH2)−シクロヘキシル、
R5は、−CN、−OH、直鎖または分枝のC1-6アルキル、−O(C1-3アルキル)、C3-6シクロアルキル、−SO2−(C1-3アルキル);メチルで置換されていてもよいピラゾリル;またはメチルで置換されていてもよいピペリジニルであり、
前記C3-6シクロアルキル基は、−NH2、−OHまたは−OCH3で置換されていてもよく、
R6は、−C(CH3)2Cl;−C(CH3)2OH;−CHC3-6シクロアルキル(OHで置換されていてもよい);イミダゾリル(メチルで置換されていてもよい);ピロリジニル(C1-3アルキルまたはオキソ基で置換されていてもよい);テトラヒドロフラニル;テトラヒドロピラニル;フェニル(1個または2個の−F、−Cl、−CN、−OH、C1-3アルキルまたは−O(C1-3アルキル)で置換されていてもよい);ナフチル;ピリジニル;フラニル;チオフェニル;オキサゾリル;チアゾリル;ピラゾリル;モルホリニル(メチルで置換されていてもよい);ベンゾチオフェニル;−CO−フェニル;または−SO2−N(C1-3アルキル)2であり、
R7は、F、−OH、−OCF3、−O−(C1-3アルキル)、−O−フェニル、−O−(CH2)m−OH、−N(C1-3アルキル)2、−NH−フェニル、ピペリジニル、ピロリジニル、アゼチジニル(azetedinyl)またはアジリジニルであり、
前記NH基内の水素原子は、C1-3アルキルで置き換えられていてもよく、
pは、1、2または3であり、
mは、2または3である)
またはその互変異性体、鏡像異性体、ジアステレオマーもしくは塩である。
X、R1、R2およびR4が、上で定義された通りであり、
R3が、メチルであるもの、
またはその互変異性体もしくは塩である。
好ましいサブグループは、
R2〜R4が、上で定義された通りであり、
Xが、CHであり、
R1が、F、Cl、CN、CH3、またはCF3である、
式(I)の化合物またはその互変異性体もしくは塩に関する。
R2〜R4が、上で定義された通りであり、
Xが、Nであり、
R1が、Hである、
式(I)の化合物またはその互変異性体もしくは塩に関する。
式(I)のより好ましい化合物は、
X、R1、R3およびR4が、上記で定義された通りであり、
R2が、
nは、1または2であるもの、
またはその互変異性体もしくは塩である。
X、R1、R3およびR4が、上で定義された通りであり、
R2が、
さらに好ましい化合物の第2の好ましいサブグループは、
X、R1、R3およびR4が、上で定義された通りであり、
R2が、
nは、1または2であり、
X、R1、R2およびR3が、上で定義された通りであり、
R4が、−CONH2、−CO−NHR5、−CO−NH−(CH2)p−R6、−CO−NH−(CH2)m−R7であり、
R5が、−CN、−OH、直鎖もしくは分枝のC1-6アルキル、−O(C1-3アルキル)、C3-6シクロアルキル、−SO2−(C1-3アルキル);メチルで置換されていてもよいピラゾリル;またはメチルで置換されていてもよいピペリジニルであり、
前記C3-6シクロアルキル基は、−NH2、−OHまたはOMeで置換されていてもよく、
R6が、−C(CH3)2Cl;−C(CH3)2OH;−CHC3-6シクロアルキル(OHで置換されていてもよい);イミダゾリル(メチルで置換されていてもよい);ピロリジニル(C1-3アルキルまたはオキソ基で置換されていてもよい);テトラヒドロフラニル;テトラヒドロピラニル;フェニル(1個または2個の−F、−Cl、−CN、−OH、C1-3アルキルまたは−O(C1-3アルキル)で置換されていてもよい);ナフチル;ピリジニル;フラニル;チオフェニル;オキサゾリル;チアゾリル;ピラゾリル;モルホリニル(メチルで置換されていてもよい);ベンゾチオフェニル;−CO−フェニル;または−SO2−N(C1-3アルキル)2であり、
R7が、F、−OH、−OCF3、−O−(C1-3アルキル)、−O−フェニル、−O−(CH2)m−OH、−N(C1-3アルキル)2、−NH−フェニル、ピロリジニル、アゼチジニル(azetedinyl)またはアジリジニルであり、
前記NH基の水素原子は、C1-3アルキルで置き換えられていてもよく、
pが、1、2または3であり、
mが、2または3である式(I)の化合物またはその互変異性体、鏡像異性体、ジアステレオマーもしくは塩である。
特に好ましいのは、
X、R1、R2およびR3が、上で定義された通りであり、
R4が、−CONH2、−CO−NHR5、−CO−NH−(CH2)p−R6、−CO−NH−(CH2)m−R7であり、
R5が、−CN、直鎖または分枝のC1-6アルキル、−O(C1-3アルキル)、C3-6シクロアルキル;メチルで置換されていてもよいピペリジニルであり、
前記C3-6シクロアルキル基は、−NH2、−OHまたはOMeで置換されていてもよく、
R6が、イミダゾリル(メチルで置換されていてもよい);ピロリジニル(C1-3アルキルまたはオキソ基で置換されていてもよい);テトラヒドロフラニル;テトラヒドロピラニル;ピリジニル;オキサゾリル;チアゾリル;ピラゾリル;モルホリニル(メチルで置換されていてもよい)であり、
R7が、F、−OH、−OCF3、−O−(C1-3アルキル)、−O−フェニル、−O−(CH2)m−OH、−N(C1-3アルキル)2、ピペリジニル、ピロリジニル、アゼチジニル(azetedinyl)またはアジリジニルであり、
前記NH基内の水素原子は、C1-3アルキルで置き換えられていてもよく、
pが、1、2または3であり、
mが、2または3である式(I)の化合物またはその互変異性体、鏡像異性体、ジアステレオマーもしくは塩である。
カルボキシ、C1-3アルコキシ−カルボニル、アミノカルボニルまたはN−(C1-3アルキル)−アミノカルボニル基であり、
上記N−(メチル)−アミノカルボニル基のメチル部分は、それぞれ炭素原子を介して結合している、ピペリジニル、N−メチル−ピペリジニルまたはモルホリニル基で置換されていてもよく、上記N−(C2-3アルキル)−アミノカルボニル基のエチル部分、プロピル部分は、ヒドロキシ、メトキシ、アミノ、N−メチル−アミノ、N,N−ジメチル−アミノ、モルホリノ、イミダゾリル、4−メチル−ピペラジニル、1−メチル−ピロリジニル、ピペリジニル、ピロリジニルまたは4−ヒドロキシ−ピペリジノ基で末端置換されていてもよい
ものである。
アミノカルボニルまたはN−(C1-3アルキル)−アミノカルボニル基であり、
上記N−(メチル)−アミノカルボニル基のメチル部分は、それぞれ炭素原子を介して結合している、ピペリジニル、N−メチル−ピペリジニルまたはモルホリニル基で置換されていてもよく、上記N−(C2-3アルキル)−アミノカルボニル基のエチル部分、プロピル部分は、ヒドロキシ、メトキシ、アミノ、N−メチル−アミノ、N,N−ジメチル−アミノ、モルホリノ、イミダゾリル、4−メチル−ピペラジニル、1−メチル−ピロリジニル、ピペリジニル、ピロリジニルまたは4−ヒドロキシ−ピペリジノ基で末端置換されていてもよい
ものである。
本発明の化合物の強力な抑制効果は、例にさらに詳細に記載されているインビトロ酵素アッセイにより判定することができる。
本発明の化合物は、以下の合成スキームに従い合成することができる。
式(1)の化合物は、互変異性体として存在することができる。本発明は、すべての互変異性体の形態を含む。さらに本発明はまた、本発明による化合物のすべての立体異性体、例えばその鏡像異性体およびジアステレオマーを含めたものを含む。本発明による化合物の個々の立体異性体は、他の異性体のないものとして、これらの混和物として、またはラセミ体として、または選択された立体異性体として実質的に存在することができる。
本明細書で使用する場合、「プロドラッグ」という用語は、以下を指す:(i)体内の代謝プロセスがそれを使用可能な形態または活性化形態に変換した後でその効果を発揮する、不活性化形態の薬物、または(ii)それ自体活性はないが、薬理学的に活性な代謝物を生じる物質(すなわち不活性な前駆物質)。
「プロドラッグ」または「プロドラッグ誘導体」という用語は、以下を意味する:その薬理学的効果(複数可)を示す前に少なくともいくらかの生体内変換を受ける親化合物または活性薬物の、共有結合した誘導体または担体。一般的に、このようなプロドラッグは、代謝的に切断可能な基を有し、例えば血中での加水分解によりインビボで急速に変換されて親化合物を生成し、一般的には親化合物のエステルおよびアミド類似体が含まれる。プロドラッグは、化学安定性の改善、患者の許容性およびコンプライアンスの改善、バイオアベイラビリティーの改善、作用持続時間の延長、器官選択性の改善、製剤の改善(例えば、水溶性の増加)、および/または副作用の低下(例えば、毒性)を目的として製剤化する。一般的に、プロドラッグ自体は、生物活性が弱いかまたは無く、普通の条件下で安定している。プロドラッグは、これらそれぞれの全体が本明細書中に参照により組み込まれている、以下に記載されているような方法などの当技術分野で公知の方法を使用して親化合物から容易に調製することができる:A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard (eds.), Gordon & Breach, 1991、特にChapter 5: “Design and Applications of Prodrugs”; Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; Prodrugs: Topical and Ocular Drug Delivery, K.B. Sloan (ed.), Marcel Dekker, 1998; Methods in Enzymology, K. Widder et al. (eds.), Vol. 42, Academic Press, 1985、特にpp. 309-396; Burger’s Medicinal Chemistry and Drug Discovery, 5th Ed., M. Wolff (ed.), John Wiley & Sons, 1995、特にVol.1およびpp. 172-178およびpp. 949-982; Pro-Drugs as Novel Delivery Systems, T. Higuchi and V. Stella (eds.), Am. Chem. Soc., 1975; Bioreversible Carriers in Drug Design, E.B. Roche (ed.), Elsevier, 1987。
本明細書で使用する場合、「C3-10シクロアルキル」または「C3-8シクロアルキル」という用語は、それぞれ3〜10個または3〜8個の環原子を有する、単環式または多環式炭素環アルキル置換基または基、例えば、シクロプロピル、シクロブチル、シクロペンチル、シクロヘキシル、シクロヘプチル、シクロブテニル、シクロペンテニル、シクロペンタジエニル、シクロヘキセニル、シクロヘキサジエニル、シクロヘプテニル、シクロヘプタジエニル、シクロヘプタトリエニル過水化ナフタレンまたはインデン、アダマンチルまたはノルボナニルなどを指す。
「C1-8アルキル」という用語は、本明細書において、単独で、または例えばアルコキシなどの場合のように他の用語と組み合わせて使用する場合、C1-8、好ましくはC1-4直鎖または分枝のアルキル/アルコキシ基、例えばメチル、エチル、プロピル(イソ−、n−)、ブチル(イソ−、n−、sec−、tert−)、ペンチル、ヘキシル、メトキシ、エトキシ、プロポキシ(イソ−、n−)、ブトキシ(イソ−、n−、sec−、tert−)、ペントキシ、ヘキソキシを指し、さらに、「C1-8アルキル」という用語にはまた、鎖内に酸素を含有することができ、ハロゲンで置換されて、エーテルまたはハロゲン化エーテル基を形成することができるアルキル基も含まれる。
「C2-8アルケニル」という用語は、それ自体でまたは別の基の一部として、直鎖内の2〜8個の炭素、好ましくは2〜6個の炭素の直鎖または分枝アルケニル基を指し、これらは、直鎖内に1個または複数の二重結合を含む、例えばビニル、2−プロペニル、3−ブテニル、2−ブテニル、4−ペンテニル、3−ペンテニル、2−ヘキセニル、3−ヘキセニル、2−ヘプテニル、3−ヘプテニル、4−ヘプテニル、3−オクテニルなどを含む。
「ヘテロアリール」という用語は、N、SおよびOより選択される1〜4個のヘテロ原子を有し、残りの環原子が炭素原子であり、好ましくは5〜10個の環原子の総数を有する、単環式または二環式の芳香族基を指す。非限定的なヘテロアリール基の例として、例えばベンゾフラニル、フリル、チエニル、ベンゾチエニル、チアゾリル、イミダゾリル、オキサゾリル、オキサジアゾリル、チアジアゾリル、ベンゾチアゾリル、トリアゾリル、テトラゾリル、イソオキサゾリル、イソチアゾリル、ピロリル、ピラニル、テトラヒドロピラニル、ピラゾリル、ピリジル、キノリニル、イソキノリニル、プリニル、カルバゾリル、ベンゾオキサゾリル、ベンズアミダゾリル、インドリル、イソインドリル、ピラジニル、ジアジニル、ピラジン、トリアジニルトリアジン、テトラジニル、テトラゾリル、ベンゾチオフェニル、ベンゾピリジルおよびベンゾイミダゾリルなどがある。
さらなる態様において、本発明は、本発明のチエノピリミジン化合物を含み、薬学的に許容される担体を含んでもよい医薬組成物を提供する。
当業者であれば、本発明の化合物および追加の治療薬を、一つの単回投与剤形へと製剤化してもよいし、または別の剤形で提供してもよく、同時投与(すなわち同じ時間に)または逐次的投与のいずれかで投与することができることを理解されよう。
本発明の化合物は、経口的、非経口的に、例えば気管支肺、皮下、静脈内、筋肉内、腹腔内、くも膜下腔内、経皮的、経粘膜、硬膜下、局在的または局所的にイオン導入により、舌下、吸入スプレーにより、エアゾールまたは直腸からなどにより、従来の薬学的に許容される賦形剤を含んでもよい投与単位製剤で投与され得る。
他の適切な薬学的に許容される賦形剤は、Remington’s Pharmaceutical Sciences, 15th Ed., Mack Publishing Co., New Jersey (1991)に記載されている。
経口投与用剤形として、錠剤、カプセル剤、ロゼンジ剤、丸剤、ウエハース、粒剤、経口用液剤、例えばシロップ剤、懸濁剤、溶液剤、乳剤、再構成用の散剤が挙げられる。
非経口投与用剤形として、点滴用の水性もしくは油性の溶液剤もしくは乳剤、注射用の予備充填したシリンジ用の水性もしくは油性の溶液剤、懸濁剤もしくは乳剤、および/または再構成用の散剤が挙げられる。
局在的/局所的投与用の剤形は、吹送法、エアゾール剤、定量エアゾール剤、経皮治療システム、薬用パッチ、直腸坐剤、および/または膣坐剤を含む。
単一剤形を製剤化するために賦形剤と合わせてもよい本発明の化合物の量は、処置する宿主および特定の投与様式に応じて変動することになる。
本発明のさらなる態様において、Mnk1もしくはMnk2(Mnk2a、Mnk2b)またはさらなるその変異体のキナーゼ活性の活性を阻害するための、特に代謝性疾患、造血障害、がんおよびこれらに続発する合併症および障害の予防および治療のための医薬組成物を生成するための、本発明のチエノピリミジン化合物の使用が提供される。この使用による炭水化物および/または脂質代謝の代謝性疾患の予防および治療が好ましい。
Mnk1および/またはMnk2(Mnk2aまたはMnk2b)および/またはさらなるその変異体のキナーゼ活性の阻害により影響を受ける本発明の疾患として、代謝性疾患の調節に関連した疾患、例えば肥満、摂食障害、カヘキシー、真性糖尿病、メタボリックシンドローム、高血圧症、冠動脈心疾患、高コレステロール血症、異脂肪血症、変形性関節炎、胆石および/または睡眠時無呼吸、ならびに活性酸素化合物(ROS防御)に関連した疾患、例えば真性糖尿病、神経変性疾患およびがんなどが挙げられる。
よって本発明のさらに好ましい実施形態において、代謝性疾患の予防または治療のための医薬組成物を製造するための、チエノピリミジン化合物の使用が提供される。
本発明のさらなる態様において、サイトカイン媒介性障害例えば炎症性疾患などの処置または予防のための医薬組成物を製造するための、本発明のチエノピリミジン化合物の使用が提供される。
よって、本発明の医薬組成物は、以下の疾患の予防または治療に有用である:炎症性疾患、特に慢性または急性炎症、慢性炎症性関節炎、関節リウマチ、乾癬性関節炎、変形性関節炎、若年性関節リウマチ、痛風性関節炎;乾癬、紅皮症性乾癬、膿疱性乾癬、炎症性腸疾患、クローン病および関連する状態、潰瘍性大腸炎、大腸炎、憩室炎、腎炎、尿道炎、卵管炎、卵巣炎、子宮内膜炎、椎骨炎、全身性エリテマトーデスおよび関連する障害、多発性硬化症、喘息、髄膜炎、脊髄炎、脳脊髄炎、脳炎、静脈炎、血栓性静脈炎、慢性閉塞性肺疾患(COPD)、炎症性肺疾患、アレルギー性鼻炎、心内膜炎、骨髄炎、リウマチ熱、リウマチ性心膜炎、リウマチ性心内膜炎、リウマチ性心筋炎、リウマチ性僧帽弁疾患、リウマチ性大動脈弁疾患、前立腺炎、前立腺膀胱炎、脊椎関節症、強直性脊椎炎、滑膜炎、腱滑膜炎、筋炎、咽頭炎、リウマチ性多発筋痛症、肩腱炎または滑液嚢炎、痛風、偽痛風、脈管炎;肉芽腫性甲状腺炎、リンパ性の甲状腺炎、侵襲性線維性甲状腺炎、急性甲状腺炎から選択される甲状腺の炎症性疾患;橋本甲状腺炎、川崎病、レイノー現象、シェーグレン症候群、神経炎症性疾患、敗血症、結膜炎、角膜炎、虹彩毛様体炎、視神経炎、耳炎、リンパ腺炎、鼻咽頭炎、副鼻腔炎、咽頭炎、扁桃炎、喉頭炎、喉頭蓋炎、気管支炎、肺炎、口内炎、歯肉炎、食道炎、胃炎、腹膜炎、肝炎、胆石症、胆嚢炎、糸球体腎炎、グッドパスチャー病、半月糸球体腎炎、膵臓炎、皮膚炎、子宮内膜炎、子宮筋層炎、子宮炎、子宮頸管炎、子宮頸内膜炎、子宮頚外膜炎、子宮傍結合組織炎、結核、膣炎、外陰炎、ケイ肺症、サルコイドーシス、じん肺症、炎症性多発性関節症、乾癬性関節症、腸線維症、気管支拡張症および腸疾患に基づく関節症。
よって、本発明のさらに好ましい実施形態において、以下から選択される炎症性疾患の予防または治療のための医薬組成物を製造するためのチエノピリミジン化合物の使用が提供される:慢性または急性炎症、慢性炎症性関節炎、関節リウマチ、乾癬、COPD、炎症性腸疾患、敗血症性ショッククローン病、潰瘍性大腸炎、多発性硬化症および喘息。
本発明の目的のために、治療有効投与量は、一般的におよそ1〜2000mg/日、好ましくはおよそ10〜およそ1000mg/日、最も好ましくはおよそ10〜およそ500mg/日であり、これらは、単回投与または多回投与で投与してもよい。
しかし、任意の特定の患者のための本発明の化合物の特異的な投与量レベルは、様々な要因、例えば年齢、性別、体重、全般的な健康状態、食生活、処置を受ける患者の個々の反応、投与時間、処置する疾患の重症度、適用される特定の化合物の活性、投与形態、適用方法および併用薬に依存することなることを理解されたい。所与の状況に対する治療有効量は、日常的試験により容易に決定され、通常の臨床医または内科医の技能および判断の範囲内である。
アッセイ原理:Mnk1、Mnk2aおよび他のキナーゼに対する化合物の阻害効力を、間接的(競合的)蛍光偏光として当業者に公知のフォーマットに基づくアッセイを用いて評価した。このアッセイ検出システムは、ホスホ特異性抗体に結合した小さな蛍光体で標識したホスホ−ペプチド(リガンドと呼ばれる)を含む。キナーゼ反応によって生成された生成物は、抗体結合に関してリガンドと競合する。溶液中でより低い回転速度を生じる結合リガンドのより大きい分子容積に基づき、その放射光は、遊離リガンドからの偏光より高い度合の偏光を有する。
例2a.Mnk1およびMnk2aのインビトロキナーゼアッセイ
酵素源として、ヒトMnk1およびヒトMnk2aを、E.coli中でGST融合タンパク質として発現させ、グルタチオンアフィニティークロマトグラフィーにより>80%均質に精製し、予備活性化したERK2を用いてインビトロで活性化した。簡単に言えば、順方向/逆方向のプライマーペア
配列番号:1 5’TTTAGGATCCGTATCTTCTCAAAAGTTGG/
配列番号:2 5’CTGGGTCGACTCAGAGTGCTGTGGGCGG
配列番号:3 5’ACAGGGATCCGTGCAGAAGAAACCAGCC/
配列番号:4 5’GATGGTCGACTCAGGCGTGGTCTCCCACC
(下線の制限酵素認識部位を利用)をそれぞれ使用して、ヒトMnk1およびMnk2aのオープン読み取り枠をcDNAから増幅し、ベクターpGEX−4T1(Amersham, Sweden, cat. no. 27-4580-01)のBamHIおよびSalI部位にクローン化した。これらの構造体は、N−末端グルタチオンSトランスフェラーゼ(GST)タグを有する融合タンパク質としてのMnk1またはMnk2a(GST−Mnk1またはGST−Mnk2aと呼ぶ)の原核性発現を可能にする。以下の発現および精製手順は、GST−Mnk1およびGST−Mnk2a(2つのアイソフォームを区別しない場合にはGST−Mnkと一般的に称する)と等しかった。GST−Mnkの発現は、E.coli BL21(Merck Biosciences、Germany、cat.no.69449)中で行った。100μg/mlアンピシリン(Sigma、Germany、cat.no.A9518)を補充したLB−Bouillon(Merck、Germany、cat.no.1.10285)中で、37℃で、細胞を培養した。培養物が0.8のA600に相当する密度に到達した際に、等量の氷冷LB/アンピシリンを添加し、培養物を25℃に移行させ、1mMイソプロピルチオガラクトシド(IPTG、Roth、Germany、cat.no.2316.4)で4時間誘発させた。遠心分離で収集した細胞を、1グラムの湿質量細胞ペレット当たり、10mlの溶解緩衝液(50mMトリス(ヒドロキシメチル)アミノメタン塩酸塩(Tris/HCl、Sigma、Germany、cat.no.T5941)pH7.5、300mM塩化ナトリウム(NaCl、Sigma、Germany、cat.no.S7653)、5%(w/v)グリセロール(Sigma、Germany、cat.no.G5516)、3mM DTTジチオトレイトール(DTT、Sigma、Germany、cat.no.D9779))に再懸濁させた。音波発生器で細胞の破壊、それに続く4℃で45分間の、38000gでの遠心分離によるクリーニングにより、溶解液を調製した。
配列番号:5 TATKSGSTTKNR
を有するカルボキシ末端アミド化12マーペプチドを合成し、高速液体クロマトグラフィー(HPLC)で>95%に精製した(Thermo、Germany)。Mnkキナーゼでリン酸化されるセリン残渣に下線が付されている。
別の例では、キナーゼ基質は、蛍光体で標識することができる。溶液中の標識された基質への試薬の結合は、文献に記載されているように蛍光偏光法の技法に従うことができる。この例の変形では、蛍光トレイサー分子は、間接的蛍光偏光法として当業者に公知の技法によりキナーゼ活性を検出するために、分析物に対する基質と競合してもよい。
方法A
方法amsl標準:
ZQ 2000MS;Waters 2996 PDA(210〜600nm);Waters 2525ポンプ;Waters 515メークアップポンプ;Waters 2767インジェクター/フラクションコレクター、Waters カラムおよびフルイディクスオーガナイザー(CFO)
移動相:
A:0.20%トリフルオロ酢酸を含む水
B:メタノール
時間(単位:min) %A %B 流速(単位:ml/min)
0.00 72 18 55.00
2.00 72 18 55.00
2.50 62 38 55.00
9.50 18 72 55.00
10.00 0 100 55.00
12.00 0 100 55.00
12.50 0 100 0
固定相:
X−terra MS C18;30×100mm*5μm
温度25℃
方法amslpolar1ベーシック:
ZQ 2000MS;Waters 2996 PDA(210〜600nm);Waters 2525ポンプ;Waters 515メークアップポンプ;Waters 2767インジェクター/フラクションコレクター、Waters カラムおよびフルイディクスオーガナイザー(CFO)
移動相:
A:0.20%トリエチルアミンを含む水
B:メタノール
時間(単位:min) %A %B 流速(単位:ml/min)
0.00 85 15 55.00
2.00 85 15 55.00
2.50 75 25 55.00
9.50 31 69 55.00
10.00 0 100 55.00
12.00 0 100 55.00
12.50 0 100 0
固定相:
X−terra MS C18;30×100mm*5μm
温度25℃
方法A_ALCMS2_10
Waters ZQ 2000;Waters 1515ポンプ;Waters PDA 996検出器;Waters 2747インジェクター
DAD 200〜420nm
移動相:
A:0.10%ギ酸を含む水
B:0.10%ギ酸を有するアセトニトリル
時間(単位:min) %A %B 流速(単位:ml/min)
0.00 95 5 1.50
2.00 0 100 1.50
2.50 0 100 1.50
2.60 95 5 1.50
固定相:
X−terra MS C18;4.6×30mm*2.5μm
方法AC1
(A_ALCMS1_1およびA_ALCMS1_3/A_ALCMS2_1およびA_ALCMS2_3)
Waters ZQ 2000;Waters 1515ポンプ;Waters PDA 996検出器;Waters 2747インジェクター
DAD 210〜420nm
移動相:
A:0.10%ギ酸を含む水
B:0.10%ギ酸を有するアセトニトリル
時間(単位:min)%A %B 流速(単位:ml/min)
0.00 95 5 1.00
0.10 95 5 1.00
3.10 2 98 1.00
4.50 2 98 1.00
5.00 95 5 1.00
方法A_ALCMS2_9
(pos/negスイッチ法)
Waters ZQ 2000;Waters 1515ポンプ;Waters PDA 996検出器;Waters 2747インジェクター
DAD 200〜420nm
移動相:
A:0.10%ギ酸を含む水
B:0.10%ギ酸を有するアセトニトリル
時間(単位:min) %A %B 流速(単位:ml/min)
0.00 95 5 1.50
2.00 0 100 1.50
2.50 0 100 1.50
2.60 95 5 1.50
固定相:
X−terra MS C18;4.6×30mm*2.5μm
移動相:
A:0.1%TFAを含む水
B:MeOH
時間(単位:min) %A %B 流速(単位:ml/min)
0.00 95 5 1.50
1.30 0 100 1.50
3.00 0 100 1.50
3.40 95 5 2.00
固定相:Waters、Sunfire、C18、3.5μm、4.6×50mm。
カラム温度:40℃で一定。
Waters ZQ2000;Waters 1515ポンプ、Waters PDA 996検出器、Waters 2747インジェクター
移動相:A 水+0.1%ギ酸
B アセトニトリル+0.1%ギ酸
勾配:
固定相:X−terra(商標)MS C18 2.5μm 4.6mm×30mm
カラム温度 約25℃
ダイオードアレイ検出波長:210〜420nm
質量:m/z80 bis800
移動相:
A:0.032% NH4OHを含む水
B:MeOH
勾配
流れ 流速(単位:ml/min)
0.00:95%A;1.0
2.00:0%A;1.0
2.50:0%A;1.0
2.60:95%A;1.0
固定相:Waters、XBridge、C18、1.7μm;2.1×50mm。
カラム温度:60℃で一定。
移動相:
A:0.1%TFAを含む水
B:0.08%TFAを含むアセトニトリル
勾配
時間(単位:min) %A %B 流速(単位:ml/min)
0.00: 95%A;1.5
2.00: 0%A;1.5
2.50: 0%A;1.5
2.60: 95%A 1.5
固定相:Waters、Sunfire、C18、3.5μm、4.6×50mm。
カラム温度:40℃で一定。
移動相:
A:0.1%TFAを含む水
B:メタノール
勾配
時間(単位:min) %A %B 流速(単位:ml/min)
0.00: 95%A;1.5
1.30: 0%A;1.5
2.50: 0%A;1.5
2.60: 95%A;1.5
固定相:Waters、Sunfire、C18、3.5μm、4.6×50mm。
カラム温度:40℃で一定。
移動相:
A:0.1%TFAを含む水
B:メタノール
勾配
時間(単位:min) %A %B 流速(単位:ml/min)
0.00: 95%A;1.5
1.30: 0%A;1.5
3.00: 0%A;1.5
3.40: 95%A;1.5
固定相:Waters、Sunfire、C18、3.5μm、4.6×50mm。
カラム温度:40℃で一定。
移動相:
A:0.1%TFAを含む水
B:メタノール
勾配
時間(単位:min) %A %B 流速(単位:ml/min)
0.00: 80%A;2
1.70: 0%A;2
2.50: 0%A;2
2.60: 95%A;2
固定相:Waters、Sunfire、C18、3.5μm、4.6×50mm。
カラム温度:60℃で一定。
移動相:
A:0.1%TFAを含む水
B:メタノール
勾配
時間(単位:min) %A %B 流速(単位:ml/min)
0.00: 80%A;2
1.70: 0%A;2
2.50: 0%A;2
2.60: 80%A;2
固定相:Waters、Sunfire、C18、3.5μm、4.6×50mm。
カラム温度:60℃で一定。
カラム:Ascentis Express、C18、2.1×50mm、2.7μm
溶媒:A% 0.1%TFAを含有するH2O;B% 0.1%TFAを含有するアセトニトリル
勾配:
時間 A% B% 流速(単位:ml/min)
0.00 95.0 5.0 1.050
1.00 5.0 95.0 1.050
1.25 5.0 95.0 1.050
1.30 95.0 5.0 1.050
カラム温度(℃)65.0
HATU:(2−(7−アザ−1H−ベンゾトリアゾール−1−イル)−1,1,3,3−テトラメチルウロニウムヘキサフルオロホスフェート)
TBTU:2−(1H−ベンゾトリアゾール−1−イル)−1,1,3,3−テトラメチルウロニウムテトラフルオルボレート(フルオルボレート)
THF:テトラヒドロフラン
EtOH:エタノール
MeOH:メタノール
DCM:塩化メチレン
DMF:N,N−ジメチルホルムアミド
EtOAc:酢酸エチル
HCl:塩酸
t−BuOH:tert.ブタノール
DTAD:ジ−ter−ブチルアゾジカーボキシレート
DEAD:アゾジカルボン酸ジエチル
DIAD:ジイソプロピルアゾジカーボキシレート
LiHMDS:リチウムヘキシメチルジシラザン
DIPEA:ジイソプロピルエチルアミン
EDC:1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド(carbodiimid)
CDI:カルボニルジイミダゾール
TFA:トリフルオロ酢酸
TEA:トリエチルアミン
brine:飽和塩化ナトリウム水溶液
rt:室温
min:分
TLC:薄層クロマトグラフィー
収量:1.78g
収量:1.45g
ESI質量スペクトル:m/z=311(M+H)+
収量:1.25g
収量:0.33g
収量:1.25g
収量:2.52g
収量:2.69g
収量:0.435g
収量:0.37g
収量:2.97g
収量:482.0mg
収量:1.8g
収量:1.6g
ESI質量スペクトル:m/z=198(M+H)+
収量:576.0mg
収量:494.0mg
収量:515.0mg
収量:476.0mg
収量:346.0mg
収量:302.0mg
収量:259.0mg
収量:168.0mg
収量:2.19g
収量:1.60g
収量:0.633g
収量:541.0mg
収量:99.0mg
収量:0.26g
収量:0.61g
4−[2−((R)−1−tert−ブトキシカルボニル−ピロリジン−3−イルオキシ)−4−フルオロ−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸メチルエステル
収量:311.0mg
収量:1.18g
4−[2−((S)−1−tert−ブトキシカルボニル−ピロリジン−3−イルオキシ)−4−フルオロ−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸メチルエステル
収量:0.89g
収量:0.61g
さらなる精製なしにこの残渣を使用した。
収量:8.26g
収量:1.25g
収量:1.265g
収量:1.01g
この反応物をクロマトグラフィー(シクロヘキサン:EE70/30→50/50)で精製した。所望の画分を合わせ、蒸発させた。粗生成物をクロマトグラフィー(シクロヘキサン:EE90/10→80/20)で精製した。生成画分を合わせ、蒸発させた。
残渣を熱いシクロヘキサンから結晶化することによって、所望の生成物を得た。
収量:8.42g
ESI質量スペクトル:m/z=259(M+NH4)+
保持時間HPLC:2.09(方法F)
収量:7.17g
ESI質量スペクトル:m/z=212(M+NH4)+
収量:4.2g(96%)
ESI質量スペクトル:m/z=225(M+H)+
収量:3.5g(96%)
ESI質量スペクトル:m/z=195(M+H)+
収量:208mg(99%)
ESI質量スペクトル:m/z=211(M+H)+
収量:166mg(93%)
ESI質量スペクトル:m/z=181(M+H)+
収量:168mg(80%)
ESI質量スペクトル:m/z=211(M+H)+
収量:77mg(32%)
ESI質量スペクトル:m/z=181(M+H)+
収量:2.33g(54%)
ESI質量スペクトル:m/z=247(M+Na)+
収量:3.8g(87%)
ESI質量スペクトル:m/z=195(M+H)+
収量:1.56g
収量:1.18g
収量:20mg
ESI質量スペクトル:m/z=403(M+H)+
保持時間HPLC:1.18(方法X)
収量:1.03g
収量:0.73g
ESI質量スペクトル:m/z=402(M+H)+
収量:26mg
ESI質量スペクトル:m/z=460(M+H)+
保持時間HPLC:1.15(方法X)
(S)−4−(4−フルオロ−2−(1−(2−ヒドロキシエチル)ピペリジン−3−イルオキシ)フェニルアミノ)−5−メチルチエノ[2,3−d]ピリミジン−6−カルボキサミド
収量:10mg
ESI質量スペクトル:m/z=446(M+H)+
保持時間HPLC:1.12(方法X)
4−[4−フルオロ−2−((S)−ピペリジン−3−イルオキシ)−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸アミドおよび対応するアルデヒドから、例6と同じように以下の化合物を調製した(表2を参照)。
収量:240mg
収量:130mg
収量:125mg
収量:45mg
ESI質量スペクトル:m/z=480(M+H)+
保持時間HPLC:1.28(方法X)
収量:710mg
ジオキサン(4M;0.5ml)中HClを添加した。この反応混合物を室温で一晩撹拌した。揮発物を真空中で取り除き、残渣をRP−クロマトグラフィーで精製することによって、所望の生成物を得た。
収量:40mg
ESI質量スペクトル:m/z=416(M+H)+
保持時間HPLC:1.15(方法X)
キラリティーが示されていない構造の場合、4−[2−((S)−1−tert−ブトキシカルボニル−ピペリジン−3−イルオキシ)−4−フルオロ−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸2,5−ジオキソ−ピロリジン−1−イルエステルと、4−[2−((R)−1−tert−ブトキシカルボニル−ピペリジン−3−イルオキシ)−4−フルオロ−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸2,5−ジオキソ−ピロリジン−1−イルエステルの混合物を使用した。
4−[4−フルオロ−2−((S)−ピペリジン−3−イルオキシ)−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸(1−メチル−1H−ピラゾール−3−イル)−アミド
収量:120mg
収量:80mg
ESI質量スペクトル:m/z=482(M+H)+
保持時間HPLC:1.19(方法X)
収量:181mg
収量:200mg
収量:77mg
収量:30.5mg
ESI質量スペクトル:m/z=452(M+H)+
保持時間HPLC:1.24(方法X)
収量:420mg
収量:30mg
ESI質量スペクトル:m/z=418(M+H)+
保持時間HPLC:1.18(方法X)
収量:72mg
収量:20mg
ESI質量スペクトル:m/z=409(M+H)+
保持時間HPLC:1.17(方法X)
収量:196mg
収量:55mg
ESI質量スペクトル:m/z=398(M+H)+
保持時間HPLC:1.15
HPLC法:方法X
収量:810mg
収量:915mg
収量:40mg
ESI質量スペクトル:m/z=385(M+H)+
保持時間HPLC:1.12(方法X)
4−[2−((S)−1−tert−ブトキシカルボニル−ピペリジン−3−イルオキシ)−4−フルオロ−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸エチルエステル
収量:1.14g
ESI質量スペクトル:m/z=331(M+H)+
保持時間HPLC:3.98(方法G)
収量:1.65g
収量:1.41g
収量:417mg
収量:222mg
ESI質量スペクトル:m/z=402(M+H)+
4−[4−フルオロ−2−((R)−1−[1,2,4]オキサジアゾール−3−イルメチル−ピペリジン−3−イルオキシ)−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸アミド
収量:31.4mg
ESI質量スペクトル:m/z=484(M+H)+
保持時間HPLC:1.14(方法X)
4−[4−フルオロ−2−((R)−ピペリジン−3−イルオキシ)−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸アミドおよびトリフルオロ−メタンスルホン酸2,2,2−トリフルオロ−エチルエステルから、例72と同じように以下の化合物を調製した。
4−{2−[(R)−1−(2,2−ジフルオロ−エチル)−ピペリジン−3−イルオキシ]−4−フルオロ−フェニルアミノ}−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸アミド
収量:57mg
ESI質量スペクトル:m/z=466(M+H)+
保持時間HPLC:1.15(方法X)
4−[4−フルオロ−2−((R)−ピペリジン−3−イルオキシ)−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸アミドおよび3−ブロモエチルメチルエーテルから、例74と同じように以下の化合物を調製した。
4−[4−フルオロ−2−((R)−1−メチル−ピペリジン−3−イルオキシ)−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸アミド
収量:86mg
ESI質量スペクトル:m/z=416(M+H)+
保持時間HPLC:1.12(方法X)
4−{2−[(R)−1−(2−シアノ−エチル)−ピペリジン−3−イルオキシ]−4−フルオロ−フェニルアミノ}−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸アミド
収量:60mg
ESI質量スペクトル:m/z=455(M+H)+
保持時間HPLC:1.14
HPLC法:方法X
収量:280mg
収量:160mg
収量:130mg
収量:60mg
ESI質量スペクトル:m/z=444(M+H)+
保持時間HPLC:1.22(方法X)
収量:180mg
収量:170mg
収量:100mg
ESI質量スペクトル:m/z=480(M+H)+
保持時間HPLC:1.28(方法X)
4−{4−フルオロ−2−[(S)−(テトラヒドロ−ピラン−3−イル)オキシ]−フェニルアミノ}−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸(3−ジメチルアミノ−プロピル)−アミド
この反応物を還流で撹拌し、2時間後室温に冷却した。冷却後、沈殿物が形成され、これを濾過した。
収量:310mg
収量:280mg
収量:20mg
ESI質量スペクトル:m/z=488(M+H)+
保持時間HPLC:1.25(方法X)
4−{4−フルオロ−2−[(R)−(テトラヒドロ−ピラン−3−イル)オキシ]−フェニルアミノ}−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸(3−ジメチルアミノ−プロピル)−アミド
収量:910mg
収量:450mg
収量:30mg
ESI質量スペクトル:m/z=488(M+H)+
保持時間HPLC:1.25(方法X)
収量:30mg
収量:65mg
ESI質量スペクトル:m/z=466(M+H)+
保持時間HPLC:1.25(方法X)
収量:120mg
収量:100mg
収量:90mg
ESI質量スペクトル:m/z=460(M+H)+
保持時間HPLC:1.22(方法X)
収量:120mg
収量:98mg
収量:36mg
ESI質量スペクトル:m/z=473(M+H)+
保持時間HPLC:1.16(方法X)
収量:543mg
収量:363mg
ESI質量スペクトル:m/z=388(M+H)+
保持時間HPLC:1.12(方法X)
収量:64mg
ESI質量スペクトル:m/z=430(M+H)+
保持時間HPLC:1.21(方法X)
4−[4−フルオロ−2−((S)−ピロリジン−3−イルオキシ)−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸アミド塩酸塩およびメタンスルホニルクロリドから、96.4と同じように以下の化合物を調製した。
収量:393mg
収量:324mg
収量:184mg
ESI質量スペクトル:m/z=388(M+H)+
保持時間HPLC:1.12(方法X)
収量:62mg
ESI質量スペクトル:m/z=430(M+H)+
保持時間HPLC:1.21(方法X)
収量:418mg
収量:128mg
収量:110mg
収量:66mg
ESI質量スペクトル:m/z=466(M+H)+
保持時間HPLC:1.24(方法X)
収量:150mg
ESI質量スペクトル:m/z=404(M+H)+
収量:130mg
ESI質量スペクトル:m/z=404(M+H)+
収量:85mg
ESI質量スペクトル:m/z=508(M+H)+
収量:15mg
ESI質量スペクトル:m/z=414(M+H)+
保持時間HPLC::1.28(方法E)
N−(4−{4−フルオロ−2−[(R)−(テトラヒドロ−フラン−3−イル)オキシ]−フェニルアミノ}−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボニル)−メタンスルホンアミド
収量:40mg
ESI質量スペクトル:m/z=467(M+H)+
保持時間HPLC::1.85(方法E)
4−{4−フルオロ−2−[(R)−(テトラヒドロ−フラン−3−イル)オキシ]−フェニルアミノ}−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸メトキシ−アミド
収量:40mg
ESI質量スペクトル:m/z=419(M+H)+
保持時間HPLC:1.68(方法E)
4−{4−フルオロ−2−[(R)−(テトラヒドロ−フラン−3−イル)オキシ]−フェニルアミノ}−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸(3−ジメチルアミノ−プロピル)−アミド
この生成物を次のステップでそのまま使用した。
収量:100mg
ESI質量スペクトル:m/z=474(M+H)+
保持時間HPLC:1.22(方法X)
4−{4−フルオロ−2−[(S)−(テトラヒドロ−フラン−3−イル)オキシ]−フェニルアミノ}−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸(3−ジメチルアミノ−プロピル)−アミド
収量:780mg
収量:650mg
この生成物を次のステップでそのまま使用する。
収量:120mg
ESI質量スペクトル:m/z=474(M+H)+
保持時間HPLC:1.22(方法X)
4−[4−フルオロ−2−((3S,5S)−5−ヒドロキシメチル−1−メタンスルホニル−ピロリジン−3−イルオキシ)−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸アミド
収量:754mg
収量:1.49g
収量:557mg
無水酢酸を0℃で添加し、触媒量のDMAPを使用した。
収量:533mg
収量:453mg
収量:367mg
収量:157mg
ESI質量スペクトル:m/z=496(M+H)+
保持時間HPLC:1.18(方法X)
4−[4−フルオロ−2−((6S,7aS)−3−オキソ−テトラヒドロ−ピロロ[1,2−c]オキサゾール−6−イルオキシ)−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸メチルエステル
収量:149mg
ESI質量スペクトル:m/z=433(M+H)+
保持時間HPLC:1.22(方法X)
収量:26mg
ESI質量スペクトル:m/z=459(M+H)+
保持時間HPLC:1.35(方法X)
4−[4−フルオロ−2−((3S,5S)−5−ヒドロキシメチル−ピロリジン−3−イルオキシ)−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸アミド
収量:32mg
ESI質量スペクトル:m/z=418(M+H)+
保持時間HPLC:1.1(方法X)
4−[4−フルオロ−2−(テトラヒドロ−ピラン−4−イルオキシ)−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸(4−メチル−モルホリン−2−イルメチル)−アミドトリフルオロ酢酸塩(trifluoracetate)
収量:13.45mg
ESI質量スペクトル:m/z=418(M+H)+
保持時間HPLC:2.47(方法F)
収量:12.15g
ESI質量スペクトル:m/z=404(M+H)+
保持時間HPLC:2.35(方法F)
収量:2.6mg
ESI質量スペクトル:m/z=516(M+H)+
保持時間HPLC:1.89(方法F)
4−[4−フルオロ−2−(テトラヒドロ−ピラン−4−イルオキシ)−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸(3−ジメチルアミノ−2−ヒドロキシ−プロピル)−アミド−塩酸塩
収量:3mg(30%)
ESI質量スペクトル:m/z=504(M+H)+
保持時間HPLC:1.70(方法L)
4−[4−フルオロ−2−(テトラヒドロ−ピラン−4−イルオキシ)−フェニルアミノ]−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸((S)−3−ヒドロキシ−1−メチル−ピペリジン−4−イル)−アミド塩酸塩
収量:22mg(53%)
ESI質量スペクトル:m/z=516(M+H)+
保持時間HPLC:1.70(方法L)
4−{4−フルオロ−2−[(R)−(テトラヒドロ−ピラン−3−イル)オキシ]−フェニルアミノ}−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸(3−ピロリジン−1−イル−プロピル)−アミド
収量:36mg(47%)
ESI質量スペクトル:m/z=514(M+H)+
保持時間HPLC:1.23(方法E)
4−{4−フルオロ−2−[(R)−(テトラヒドロ−ピラン−3−イル)オキシ]−フェニルアミノ}−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸(1−メチル−ピペリジン−4−イル)−アミド
収量:51mg(69%)
ESI質量スペクトル:m/z=500(M+H)+
保持時間HPLC:1.21(方法E)
収量:1.4g(76%)
ESI質量スペクトル:m/z=401(M+H)+
収量:1.3g(96%)
ESI質量スペクトル:m/z=387(M+H)+
収量:45mg(41%)
ESI質量スペクトル:m/z=430(M+H)+
保持時間HPLC:1.54(方法E)
収量:569mg
収量:823mg(97%)
保持時間HPLC:2.3(方法K)
収量:72mg(44%)
ESI質量スペクトル:m/z=372(M+H)+
保持時間HPLC:2.12(方法K)
5−メチル−4−{2−[(R)−(テトラヒドロ−フラン−3−イル)オキシ]−ピリジン−3−イルアミノ}−チエノ[2,3−d]ピリミジン−6−カルボン酸(3−ジメチルアミノ−プロピル)−アミドトリフルオロ酢酸塩
収量:211mg(84%)
ESI質量スペクトル:m/z=457(M+H)+
保持時間HPLC:1.79(方法K)
収量:70mg(69%)
収量:301mg
保持時間HPLC:2.33(方法K)
収量:7mg(31%)
ESI質量スペクトル:m/z=372(M+H)+
保持時間HPLC:2.03(方法K)
5−メチル−4−{2−[(S)−(テトラヒドロ−フラン−3−イル)オキシ]−ピリジン−3−イルアミノ}−チエノ[2,3−d]ピリミジン−6−カルボン酸(3−ジメチルアミノ−プロピル)−アミド
収量:26mg(94%)
ESI質量スペクトル:m/z=456(M)+
保持時間HPLC:1.57(方法M)
4−{4−フルオロ−2−[(S)−(テトラヒドロ−フラン−3−イル)オキシ]−フェニルアミノ}−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸(1−メチル−ピペリジン−4−イル)−アミド
収量:222mg(89%)
ESI質量スペクトル:m/z=486(M+H)+
保持時間HPLC:1.28(方法C)
4−[(4−{4−フルオロ−2−[(S)−(テトラヒドロ−フラン−3−イル)オキシ]−フェニルアミノ}−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボニル)−アミノ]−アゼパン−1−カルボン酸tert−ブチルエステル
収量:457mg(100%)
ESI質量スペクトル:m/z=586(M+H)+
保持時間HPLC:1.95(方法C)
4−{4−フルオロ−2−[(S)−(テトラヒドロ−フラン−3−イル)オキシ]−フェニルアミノ}−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸アゼパン−4−イルアミドトリフルオロ酢酸塩
収量:382mg(98%)
ESI質量スペクトル:m/z=486(M+H)+
保持時間HPLC:1.29(方法D)
4−{4−フルオロ−2−[(R)−(テトラヒドロ−フラン−3−イル)オキシ]−フェニルアミノ}−5−メチル−チエノ[2,3−d]ピリミジン−6−カルボン酸アゼパン−4−イルアミドトリフルオロ酢酸塩
収量:435mg(100%)
ESI質量スペクトル:m/z=486(M+H)+
保持時間HPLC:1.88(方法D)
5−メチル−4−[2−(テトラヒドロ−ピラン−4−イルオキシ)−ピリジン−3−イルアミノ]−チエノ[2,3−d]ピリミジン−6−カルボン酸((1S,2S)−2−ヒドロキシ−シクロペンチル)−アミド
収量:635mg(77%)
ESI質量スペクトル:m/z=401(M+H)+
収量:571mg(93%)
ESI質量スペクトル:m/z=387(M+H)+
保持時間HPLC:2.87(方法D)
収量:100mg(82%)
ESI質量スペクトル:m/z=470(M+H)+
保持時間HPLC:2.62(方法D)
5−メチル−4−[2−(テトラヒドロ−ピラン−4−イルオキシ)−ピリジン−3−イルアミノ]−チエノ[2,3−d]ピリミジン−6−カルボン酸(3−メタンスルフィニル−プロピル)−アミド
収量:37mg(36%)
ESI質量スペクトル:m/z=490(M+H)+
保持時間HPLC:2.33(方法D)
Claims (19)
- 以下の一般式
の化合物
(式中、
Xは、CHまたはNであり、
R1は、H、ハロゲン、CN、CH3またはCF3であり、
R2は、
−SO2−(C1-3アルキル)、−CO−(C1-3アルキル)、−CO−(CH2)n−O−(C1-3アルキル)、−CO−(CH2)n−N(C1-3アルキル)2、C1-4アルキル、−(CH2)n−CF3、−(CH2)n−CHF2、−(CH2)n−OH、−(CH2)n−O−(C1-3アルキル)、−(CH2)n−CN、
炭素原子において、−CH2OH基で置換されていてもよく、
nは、1または2であり、
さらに、前記
nは、1または2であり、
R3は、C1-2アルキル基であり、
R4は、−COOH、−CO2−(C1-3アルキル)、−CO2−(CH2)n−N(C1-3アルキル)2、−CONH2、−CO−NHR5、−CO−NH−(CH2)p−R6、−CO−NH−(CH2)m−R7、−CO−N(CH3)−(CH2)m−R7、CO−N(CH3)−(CH2)−シクロヘキシル、
R5は、−CN、−OH、直鎖または分枝のC1-6アルキル、−O(C1-3アルキル)、C3-6シクロアルキル、−SO2−(C1-3アルキル);メチルで置換されていてもよいピラゾリル;またはメチルで置換されていてもよいピペリジニルであり、
前記C3-6シクロアルキル基は、−NH2、−OHまたは−OCH3で置換されていてもよく、
R6は、−C(CH3)2Cl;−C(CH3)2OH;−CHC3-6シクロアルキル(OHで置換されていてもよい);イミダゾリル(メチルで置換されていてもよい);ピロリジニル(C1-3アルキルまたはオキソ基で置換されていてもよい);テトラヒドロフラニル;テトラヒドロピラニル;フェニル(1個または2個の−F、−Cl、−CN、−OH、C1-3アルキルまたは−O(C1-3アルキル)で置換されていてもよい);ナフチル;ピリジニル;フラニル;チオフェニル;オキサゾリル;チアゾリル;ピラゾリル;モルホリニル(メチルで置換されていてもよい);ベンゾチオフェニル;−CO−フェニル;または−SO2−N(C1-3アルキル)2であり、
R7は、F、−OH、−OCF3、−O−(C1-3アルキル)、−O−フェニル、−O−(CH2)m−OH、−N(C1-3アルキル)2、−NH−フェニル、ピペリジニル、ピロリジニル、アゼチジニル(azetedinyl)またはアジリジニルであり、
前記NH基内の水素原子は、C1-3アルキルで置き換えられていてもよく、
pは、1、2または3であり、
mは、2または3である)
またはその互変異性体、鏡像異性体、ジアステレオマーもしくは塩。 - X、R1、R2およびR4が、請求項1において定義された通りであり、
R3が、メチルである、
請求項1に記載の式(I)の化合物またはその互変異性体もしくは塩。 - R2〜R4が、請求項1で定義された通りであり、
Xが、CHであり、
R1が、F、Cl、CN、CH3またはCF3である、
請求項1または2に記載の式(I)の化合物またはその互変異性体もしくは塩。 - R2〜R4が、請求項1で定義された通りであり、
Xが、Nであり、
R1が、Hである、
請求項1または2に記載の式(I)の化合物またはその互変異性体もしくは塩。 - X、R1、R3およびR4が、請求項1から4のいずれか1項で定義された通りであり、R2が、
nは、1または2であり、
さらに、前記
請求項1から4のいずれか1項に記載の式(I)の化合物またはその互変異性体もしくは塩。 - X、R1、R2およびR3が、請求項1から7のいずれか1項に定義された通りであり、R4が、−CONH2、−CO−NHR5、−CO−NH−(CH2)p−R6、−CO−NH−(CH2)m−R7であり、
R5が、−CN、−OH、直鎖もしくは分枝のC1-6アルキル、−O(C1-3アルキル)、C3-6シクロアルキル、−SO2−(C1-3アルキル);メチルで置換されていてもよいピラゾリル;またはメチルで置換されていてもよいピペリジニルであり、
前記C3-6シクロアルキル基は、−NH2、−OHまたはOMeで置換されていてもよく、R6が、−C(CH3)2Cl;−C(CH3)2OH;−CHC3-6シクロアルキル(OHで置換されていてもよい);イミダゾリル(メチルで置換されていてもよい);ピロリジニル(C1-3アルキルまたはオキソ基で置換されていてもよい);テトラヒドロフラニル;テトラヒドロピラニル;フェニル(1個または2個の−F、−Cl、−CN、−OH、C1-3アルキルまたは−O(C1-3アルキル)で置換されていてもよい);ナフチル;ピリジニル;フラニル;チオフェニル;オキサゾリル;チアゾリル;ピラゾリル;モルホリニル(メチルで置換されていてもよい);ベンゾチオフェニル;−CO−フェニル;または−SO2−N(C1-3アルキル)2であり、
R7が、F、−OH、−OCF3、−O−(C1-3アルキル)、−O−フェニル、−O−(CH2)m−OH、−N(C1-3アルキル)2、−NH−フェニル、ピロリジニル、アゼチジニル(azetedinyl)またはアジリジニルであり、
前記NH基の水素原子は、C1-3アルキルで置き換えられていてもよく、
pが、1、2または3であり、
mが、2または3である、
請求項1に記載の式(I)の化合物、またはその互変異性体、鏡像異性体、ジアステレオマーもしくは塩。 - X、R1、R2およびR3が、請求項1から7のいずれか1項に定義された通りであり、R4が、−CONH2、−CO−NHR5、−CO−NH−(CH2)p−R6、−CO−NH−(CH2)m−R7であり、
R5が、−CN、直鎖または分枝のC1-6アルキル、−O(C1-3アルキル)、C3-6シクロアルキル;メチルで置換されていてもよいピペリジニルであり、
前記C3-6シクロアルキル基は、−NH2、−OHまたはOMeで置換されていてもよく、R6が、イミダゾリル(メチルで置換されていてもよい);ピロリジニル(C1-3アルキルまたはオキソ基で置換されていてもよい);テトラヒドロフラニル;テトラヒドロピラニル;ピリジニル;オキサゾリル;チアゾリル;ピラゾリル;モルホリニル(メチルで置換されていてもよい)であり、
R7が、F、−OH、−OCF3、−O−(C1-3アルキル)、−O−フェニル、−O−(CH2)m−OH、−N(C1-3アルキル)2、ピペリジニル、ピロリジニル、アゼチジニル(azetedinyl)またはアジリジニルであり、
前記NH基内の水素原子は、C1-3アルキルで置き換えられていてもよく、
pが、1、2または3であり、
mが、2または3である、
請求項1に記載の式(I)の化合物、またはその互変異性体、鏡像異性体、ジアステレオマーもしくは塩。 - 請求項1から10のいずれか1項に記載の化合物の薬学的に許容される塩。
- 請求項1から10のいずれか1項に記載の化合物または請求項11に記載の塩を含む医薬組成物。
- 追加の治療薬をさらに含む、請求項12に記載の医薬組成物。
- 追加の治療薬が、抗糖尿病剤、脂質低下剤、心臓血管薬剤、抗高血圧剤、利尿剤、血小板凝集阻害剤、抗腫瘍剤または抗肥満剤から選択される、請求項13に記載の医薬組成物。
- 代謝性疾患、造血障害、神経変性疾患、腎障害、炎症性障害およびがんならびにこれらに続発する合併症および疾患の予防または治療に使用するための、請求項1から10のいずれか1項に記載の化合物または請求項11に記載の塩を含む医薬組成物。
- 炭水化物および/または脂質代謝の代謝性疾患ならびにこれらに続発する合併症および障害の予防または治療に使用するための、請求項1から10のいずれか1項に記載の化合物または請求項11に記載の塩を含む医薬組成物。
- 糖尿病の予防または治療に使用するための、請求項1から10のいずれか1項に記載の化合物または請求項11に記載の塩を含む医薬組成物。
- 追加の治療薬と組み合わせて、患者へ同時投与または逐次投与を行うための、請求項1から10のいずれか1項に記載の化合物または請求項11に記載の塩を含む医薬組成物。
- 経口的、非経口的、局在的または局所的適用に適応するための、請求項12から18のいずれか1項に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10154925 | 2010-02-26 | ||
EP10154925.1 | 2010-02-26 | ||
PCT/EP2011/052810 WO2011104337A1 (en) | 2010-02-26 | 2011-02-25 | Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013520472A JP2013520472A (ja) | 2013-06-06 |
JP5639197B2 true JP5639197B2 (ja) | 2014-12-10 |
Family
ID=43902874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012554347A Active JP5639197B2 (ja) | 2010-02-26 | 2011-02-25 | 医薬組成物のためのヘテロシクロアルキル含有チエノピリミジン |
Country Status (15)
Country | Link |
---|---|
US (1) | US8648068B2 (ja) |
EP (1) | EP2539346B1 (ja) |
JP (1) | JP5639197B2 (ja) |
KR (1) | KR20120130052A (ja) |
CN (1) | CN102869669A (ja) |
AR (1) | AR080327A1 (ja) |
AU (1) | AU2011219761A1 (ja) |
BR (1) | BR112012021264A2 (ja) |
CA (1) | CA2791105A1 (ja) |
CL (1) | CL2012002318A1 (ja) |
EA (1) | EA201201193A1 (ja) |
MX (1) | MX2012009409A (ja) |
TW (1) | TW201141482A (ja) |
UY (1) | UY33241A (ja) |
WO (1) | WO2011104337A1 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5301986B2 (ja) * | 2005-06-22 | 2013-09-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物用のチエノピリミジン類 |
KR20090047391A (ko) * | 2006-04-07 | 2009-05-12 | 데벨로겐 악틴게젤샤프트 | 약제학적 조성물을 위한 Mnk1/Mnk2 억제 활성을 갖는티에노피리미딘 |
EP1889847A1 (en) * | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
EP2331551B1 (en) | 2008-08-26 | 2016-06-29 | Evotec International GmbH | Thienopyrimidines for pharmaceutical compositions |
CA2791114A1 (en) * | 2010-02-26 | 2011-09-01 | Boehringer Ingelheim International Gmbh | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
SG183484A1 (en) | 2010-02-26 | 2012-09-27 | Japan Tobacco Inc | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
UY33241A (es) | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
EP2539345B1 (en) * | 2010-02-26 | 2015-07-22 | Boehringer Ingelheim International GmbH | 4-[cycloalkyloxy(hetero)arylamino]-thieno[2,3-d]pyrimidines having mnk1/ mnk2 inhibiting activity for pharmaceutical compositions |
GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
WO2013174744A1 (en) | 2012-05-21 | 2013-11-28 | Bayer Pharma Aktiengesellschaft | Thienopyrimidines |
CN104470931B (zh) | 2012-05-21 | 2016-10-26 | 拜耳医药股份有限公司 | 取代的苯并噻吩并嘧啶 |
MX367055B (es) | 2012-06-26 | 2019-08-02 | Del Mar Pharmaceuticals | El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa. |
TW201412740A (zh) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
CN105189518A (zh) | 2013-02-01 | 2015-12-23 | 拜耳制药股份公司 | 取代的噻吩并吡啶和其药物用途 |
WO2014118226A1 (en) | 2013-02-01 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolopyrimidinylamino-indazoles |
JP2016512491A (ja) | 2013-03-06 | 2016-04-28 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換チアゾロピリミジン類 |
US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
CN103417545B (zh) * | 2013-08-02 | 2014-12-31 | 上海市第十人民医院 | 一种吡唑并嘧啶类化合物在制备抗烟曲霉菌感染性疾病药物中的应用 |
CN103356626B (zh) * | 2013-08-02 | 2015-01-07 | 上海市第十人民医院 | 吡唑并嘧啶类化合物在制备抗红色毛癣菌感染疾病药物中的应用 |
CN103356627B (zh) * | 2013-08-02 | 2014-10-29 | 上海市第十人民医院 | 一种药物在光滑假丝酵母菌感染性疾病应用 |
CN103356625B (zh) * | 2013-08-02 | 2014-10-29 | 上海市第十人民医院 | 嗓唑并嘧啶类在近平滑假丝酵母菌感染性疾病应用 |
CN103356628B (zh) * | 2013-08-02 | 2014-10-29 | 上海市第十人民医院 | 嗓唑并嘧啶类化合物在制药中的应用 |
CN103356624B (zh) * | 2013-08-02 | 2014-12-31 | 上海市第十人民医院 | 一种嘧啶类化合物在制备抗真菌药物中的应用 |
US9512084B2 (en) * | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
CA2929742C (en) * | 2013-12-04 | 2022-09-20 | Evotec International Gmbh | Sulfoximine substituted quinazolines for pharmaceutical compositions |
WO2015091156A1 (en) * | 2013-12-17 | 2015-06-25 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions |
JP6479854B2 (ja) * | 2014-05-07 | 2019-03-06 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングEvotec International GmbH | 医薬組成物のためのスルホキシイミン置換キナゾリン |
GB201520500D0 (en) * | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
WO2017165908A1 (en) * | 2016-03-31 | 2017-10-05 | South Australian Health And Medical Research Institute Limited | Method of inhibiting high fat diet-related conditions |
WO2019023651A2 (en) | 2017-07-28 | 2019-01-31 | Massachusetts Institute Of Technology | MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH408945A (de) | 1956-02-10 | 1966-03-15 | Ciba Geigy | Verfahren zur Herstellung von heterocyclischen Verbindungen |
DE3036390A1 (de) | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen |
DD248593A1 (de) | 1985-01-11 | 1987-08-12 | Univ Halle Wittenberg | Verfahren zur herstellung von 4-basischsubstituierten thieno/2,3-d/pyrimidin-6-ylcarbonsaeureestern |
DE4008726A1 (de) | 1990-03-19 | 1991-09-26 | Basf Ag | Thieno(2,3-d)pyrimidinderivate |
CA2039411A1 (en) | 1990-03-30 | 1991-10-01 | Ronnie Gerald Edie | Thienopyrimidine derivatives |
TW444018B (en) | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
ES2109796T3 (es) * | 1994-05-03 | 1998-01-16 | Ciba Geigy Ag | Derivados de pirrolopirimidilo con efecto antiproliferante. |
EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases |
US6395733B1 (en) * | 1995-06-07 | 2002-05-28 | Pfizer Inc | Heterocyclic ring-fused pyrimidine derivatives |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
WO1999024440A1 (en) | 1997-11-11 | 1999-05-20 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
US20030162795A1 (en) * | 1998-10-22 | 2003-08-28 | Pfizer Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
US6643277B2 (en) | 2000-06-29 | 2003-11-04 | Harris Broadband Wireless Access, Inc. | Frequency re-use for point to multipoint applications |
JP2002020386A (ja) * | 2000-07-07 | 2002-01-23 | Ono Pharmaceut Co Ltd | ピラゾロピリジン誘導体 |
WO2002088138A1 (en) | 2001-04-30 | 2002-11-07 | Bayer Corporation | Novel 4-amino-5,6-substituted thiopheno[2,3-d]pyrimidines |
SE0102147D0 (sv) | 2001-06-18 | 2001-06-18 | Pharmacia Ab | New methods |
US20050080026A1 (en) | 2001-10-29 | 2005-04-14 | Arnd Steuernagel | Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism |
AU2003274652A1 (en) | 2002-10-23 | 2004-05-13 | Obetherapy Biotechnology | Compounds, compositions and methods for modulating fat metabolism |
US20050012622A1 (en) | 2003-05-19 | 2005-01-20 | Sutton William R. | Monitoring and control of sleep cycles |
US7589086B2 (en) | 2003-05-28 | 2009-09-15 | Universita Degli Studi Di Siena | Substituted pyrazolo[3,4-D]pyrimidines as anti-tumor agents |
KR20060021905A (ko) | 2003-06-20 | 2006-03-08 | 셀테크 알앤디 리미티드 | 키나아제 억제제로서의 티에노피리돈 유도체 |
EP1651652B1 (en) | 2003-07-24 | 2006-12-27 | Bayer Pharmaceuticals Corporation | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders |
US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
DE10351436A1 (de) * | 2003-11-04 | 2005-06-09 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
DE602005024511D1 (de) * | 2004-01-05 | 2010-12-16 | Merz Pharma Gmbh & Co Kgaa | Memantin für die behandlung von leichtem bis mittelschwerem morbus alzheimer |
EP1724268A4 (en) | 2004-02-20 | 2010-04-21 | Kirin Pharma Kk | COMPOUND HAVING TGF-BETA INHIBITING ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
US20080269238A1 (en) * | 2004-04-01 | 2008-10-30 | Takeda Pharmaceutical Company Limited | Thiazolopyrimidine Derivative |
GB0412467D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
WO2006014325A2 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
EP1746099A1 (en) | 2004-12-23 | 2007-01-24 | DeveloGen Aktiengesellschaft | Mnk1 or Mnk2 inhibitors |
US7943357B2 (en) | 2005-03-08 | 2011-05-17 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Crystallographic structure of Mnk-1 and Mnk-2 proteins |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
ES2623221T3 (es) | 2005-05-20 | 2017-07-10 | Methylgene Inc | Inhibidores de la señalización del receptor de VEGF y del receptor de HGF |
JP5301986B2 (ja) * | 2005-06-22 | 2013-09-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物用のチエノピリミジン類 |
US20070099877A1 (en) * | 2005-11-02 | 2007-05-03 | Cytovia, Inc. | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US20070213305A1 (en) | 2005-11-02 | 2007-09-13 | Cytovia, Inc. | N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2007059905A2 (en) * | 2005-11-25 | 2007-05-31 | Develogen Aktiengesellschaft | Thienopyrimidines treating inflammatory diseases |
WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
WO2007084815A2 (en) | 2006-01-19 | 2007-07-26 | Janssen Pharmaceutica, N.V. | Substituted thienopyrimidine kinase inhibitors |
KR20090047391A (ko) * | 2006-04-07 | 2009-05-12 | 데벨로겐 악틴게젤샤프트 | 약제학적 조성물을 위한 Mnk1/Mnk2 억제 활성을 갖는티에노피리미딘 |
WO2007147874A1 (en) | 2006-06-22 | 2007-12-27 | Biovitrum Ab (Publ) | Pyridine and pyrazine derivatives as mnk kinase inhibitors |
EP1889847A1 (en) * | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
JP2011504474A (ja) * | 2007-11-22 | 2011-02-10 | ベーリンガー インゲルハイム インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルツハイマー氏病を治療するためのMnkインヒビターの使用 |
JP5779778B2 (ja) * | 2007-11-28 | 2015-09-16 | ダナ−ファーバー キャンサー インスティテュート インク.Dana−Farber Cancer Institute, Inc. | Bcr−ablの低分子のミリスチン酸エステル阻害剤及びその使用方法 |
EP2458912B1 (en) * | 2008-01-25 | 2014-06-04 | Huawei Technologies Co., Ltd. | Method and mobile station apparatus transmitting uplink data |
US20100015708A1 (en) * | 2008-06-18 | 2010-01-21 | Mdrna, Inc. | Ribonucleic acids with non-standard bases and uses thereof |
EP2331551B1 (en) * | 2008-08-26 | 2016-06-29 | Evotec International GmbH | Thienopyrimidines for pharmaceutical compositions |
WO2011104338A1 (en) | 2010-02-26 | 2011-09-01 | Boehringer Ingelheim International Gmbh | Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
UY33241A (es) | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
EP2539345B1 (en) * | 2010-02-26 | 2015-07-22 | Boehringer Ingelheim International GmbH | 4-[cycloalkyloxy(hetero)arylamino]-thieno[2,3-d]pyrimidines having mnk1/ mnk2 inhibiting activity for pharmaceutical compositions |
CA2791114A1 (en) * | 2010-02-26 | 2011-09-01 | Boehringer Ingelheim International Gmbh | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
EP2567807B1 (de) * | 2011-09-07 | 2016-05-11 | Nordex Energy GmbH | Verfahren zur Herstellung eines Windenergieanlagenrotorblattbauteils mit einem vorgefertigten Hauptgurt |
-
2011
- 2011-02-24 UY UY0001033241A patent/UY33241A/es not_active Application Discontinuation
- 2011-02-25 AR ARP110100601A patent/AR080327A1/es unknown
- 2011-02-25 KR KR1020127022310A patent/KR20120130052A/ko not_active Application Discontinuation
- 2011-02-25 CA CA2791105A patent/CA2791105A1/en not_active Abandoned
- 2011-02-25 AU AU2011219761A patent/AU2011219761A1/en not_active Abandoned
- 2011-02-25 WO PCT/EP2011/052810 patent/WO2011104337A1/en active Application Filing
- 2011-02-25 TW TW100106540A patent/TW201141482A/zh unknown
- 2011-02-25 BR BR112012021264A patent/BR112012021264A2/pt not_active Application Discontinuation
- 2011-02-25 US US13/034,913 patent/US8648068B2/en active Active
- 2011-02-25 MX MX2012009409A patent/MX2012009409A/es not_active Application Discontinuation
- 2011-02-25 JP JP2012554347A patent/JP5639197B2/ja active Active
- 2011-02-25 EA EA201201193A patent/EA201201193A1/ru unknown
- 2011-02-25 EP EP11707387.4A patent/EP2539346B1/en active Active
- 2011-02-25 CN CN2011800209929A patent/CN102869669A/zh active Pending
-
2012
- 2012-08-21 CL CL2012002318A patent/CL2012002318A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EA201201193A1 (ru) | 2013-04-30 |
CL2012002318A1 (es) | 2012-11-23 |
US20110212102A1 (en) | 2011-09-01 |
AR080327A1 (es) | 2012-03-28 |
KR20120130052A (ko) | 2012-11-28 |
TW201141482A (en) | 2011-12-01 |
EP2539346B1 (en) | 2014-04-16 |
CN102869669A (zh) | 2013-01-09 |
US8648068B2 (en) | 2014-02-11 |
CA2791105A1 (en) | 2011-09-01 |
WO2011104337A1 (en) | 2011-09-01 |
EP2539346A1 (en) | 2013-01-02 |
BR112012021264A2 (pt) | 2016-05-17 |
JP2013520472A (ja) | 2013-06-06 |
AU2011219761A1 (en) | 2012-08-16 |
MX2012009409A (es) | 2012-09-07 |
UY33241A (es) | 2011-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5639197B2 (ja) | 医薬組成物のためのヘテロシクロアルキル含有チエノピリミジン | |
JP5575275B2 (ja) | 医薬組成物のための置換アルキル基含有チエノピリミジン | |
JP5675614B2 (ja) | 医薬組成物用のチエノピリミジン | |
JP5575274B2 (ja) | 医薬組成物のためのmnkl/mnk2阻害活性を有する4−[シクロアルキルオキシ(ヘテロ)アリールアミノ]チエノ「2,3−d]ピリミジン | |
EP2539344B1 (en) | Halogen or cyano substituted thieno[2,3-d]pyrimidines having mnk1/ mnk2 inhibiting activity for pharmaceutical compositions | |
JP6549109B2 (ja) | スルホキシイミン置換キナゾリンならびにmnk1および/またはmnk2キナーゼ阻害薬としてのその使用 | |
JP6306035B2 (ja) | 医薬組成物のためのスルホキシミン置換キナゾリン | |
JP6479854B2 (ja) | 医薬組成物のためのスルホキシイミン置換キナゾリン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20140303 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140603 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140623 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140922 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141015 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141023 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5639197 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |